N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamide

JP2023554405A5Active Publication Date: 2024-11-06ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023536454
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-17
Filing Date
2021-12-16
Publication Date
2024-11-06
Estimated Expiration
2041-12-16

AI Technical Summary

Technical Problem

There is a lack of pharmacological agents that effectively inhibit fibroblast activation protein (FAP) activity, which is associated with the exacerbation of non-alcoholic steatohepatitis (NASH) and other diseases, necessitating the development of FAP inhibitors with appropriate pharmacological selectivity and bioavailability.

Method used

The development of N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamide compounds and their pharmaceutically acceptable salts, which are designed to target and inhibit FAP activity, thereby treating or preventing FAP-mediated conditions such as NASH, liver disease, type 2 diabetes, cardiovascular conditions, obesity, fibrosis, and cancer.

Benefits of technology

These compounds provide therapeutic benefits by inhibiting FAP activity, potentially reducing disease severity and progression in conditions like NASH, offering a novel approach to managing FAP-related pathologies with improved selectivity and bioavailability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022130270000001
    Figure 2022130270000001
  • Figure 2022130270000002
    Figure 2022130270000002
  • Figure 2022130270000003
    Figure 2022130270000003
Patent Text Reader

Abstract

A compound having the structure of formula (I): [Formula 1] JPEG2023554405000852.jpg59160 and pharmaceutically acceptable salts thereof (wherein X 1 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is as defined herein); pharmaceutical compositions comprising such compounds and salts; uses of such compounds and salts for treating or preventing conditions mediated by the prolyl endopeptidase fibroblast activation protein (FAP); kits comprising such compounds and salts; and methods for preparing such compounds and salts.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The present disclosure generally relates to N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamide and pharmaceutically acceptable salts thereof. The present specification further describes pharmaceutical compositions comprising such compounds and salts; such compounds and salts for treating or preventing pathologies mediated by the prolyl endopeptidase fibroblast activation protein (FAP). Uses of salts; kits containing such compounds and salts; and methods for making such compounds and salts. [Background technology]

[0002] FAP, a type II transmembrane serine protease, is expressed by fibroblast-like cells involved in tissue repair and healing. In the context of non-alcoholic steatohepatitis (NASH), FAP is up-regulated on the cell surface of activated hepatic stellate cells involved in fibrosis formation (Non-patent Document 1) and is associated with NASH predicting disease prognosis. This is the main aspect of (Non-Patent Document 2). FAP can also exist as a shed plasma protease. Increased levels of circulating FAP are associated with NASH disease severity (3).

[0003] FAP has a consensus cleavage motif after Gly-Pro and exhibits both endopeptidase and exopeptidase activities. Known enzymatic activities include cleavage of collagen (Non-Patent Document 1), α2-antiplasmin (α2AP) (Non-Patent Document 4), and Fibroblast Growth Factor 21 (FGF21) (Non-Patent Document 5) . FAP activity (including collagen cleavage) on the cell surface of activated fibroblasts generates a profibrotic environment. FAP cleavage of α2AP results in more efficient cross-linking of α2AP to fibrin, causing reduced fibrin clearance. FAP cleavage of FGF21 inactivates the metabolic effects of FGF21 (Non-Patent Document 5). All these activities are associated with exacerbation of NASH disease, and inhibition of FAP has the potential to treat NASH and other pathological conditions by affecting multiple mechanisms.

[0004] Inhibition of FAP activity is a currently undeveloped therapeutic approach to treat NASH and other diseases associated with such activity. There are currently no approved pharmacological agents available that either broadly inhibit FAP activity or specifically inhibit FAP activity. Accordingly, there is a need for FAP inhibitors, particularly FAP inhibitors that have pharmacologically appropriate selectivity and bioavailability and are therefore suitable for administration to subjects in need of such treatment. The present disclosure addresses this broad unmet need by providing such compounds and corresponding pharmaceutical compositions and methods for the treatment or prevention of NASH and related pathologies. [Prior art documents] [Non-patent literature]

[0005] [Non-patent document 1] Hepatology 1999,29,1768 [Non-patent document 2] Gastroenterology 2020,158,1611 [Non-patent document 3] Diabetes Res Clin Pract 2015,108,466 [Non-patent document 4] Blood 2004 103,3783 [Non-patent document 5] Biochem J 2016,473,605 [Summary of the invention] [Means to solve the problem]

[0006] In one aspect, the present disclosure provides compounds having the structure of formula (I): [ka] and a pharmaceutically acceptable salt thereof (wherein, X 1 -S-, -S(O)-, and -S(O) 2 - selected from the group consisting of; R 1 is hydrogen, halogen, hydroxy, C 1~3 -alkyl, and C 1~6 - selected from the group consisting of alkoxy; R 2 teeth, (a) Heterocyclyl containing a total of 4 to 10 ring atoms (a heterocyclyl ring is: (i) a saturated, partially saturated, or fully unsaturated monocyclic or fused bicyclic ring; and (ii) 1 , 2, or 3 nitrogen ring atoms, the remaining ring atoms are carbon, and (iii) halogen, hydroxy, oxo, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 - optionally substituted with one or more substituents independently selected from the group consisting of alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl; C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 -alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl may be further substituted with one or more halogens, and (b) C 1~6 The alkyl may be further substituted with one or more hydroxy); (b) heterocyclyl containing a total of 5 to 10 ring atoms; a heterocyclyl ring is: (i) a saturated, partially saturated, or fully unsaturated monocyclic or fused bicyclic ring; and (ii) a) has one nitrogen ring atom and one oxygen ring atom, and the remaining ring atoms are carbon; or (b) has one nitrogen ring atom and one sulfur ring atom; The remaining ring atoms are carbon, and (iii) halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl may be further substituted with one or more halogens); and (c) a spiroheterocyclyl containing a total of 6 to 11 ring atoms; a spiroheterocyclyl: (i) contains two saturated rings; (ii) has (a) 1 or 2 nitrogen ring atoms; , the remaining ring atoms are carbon, or (b) have 1 or 2 nitrogen ring atoms and 1 or 2 oxygen ring atoms, and the remaining ring atoms are carbon, or (c) 1 nitrogen ring atoms and one sulfur ring atom, the remaining ring atoms are carbon, and (iii) halogen, oxo, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6-alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl) selected from the group consisting of; R 3 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl; R 4 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl; R 5 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl; and R 6 is hydrogen, halogen, and C 1~3 -alkyl).

[0007] In another aspect, the present disclosure provides formula (II), (III-A), (III-B), (III-C), (III-D), (III -E), (IV), (IV-A), (V), (VI), (VII), (VIII), (IX), (X), or (XI), and their Pharmaceutically acceptable salts are provided.

[0008] In another aspect, the disclosure provides therapeutically effective amounts of formulas (I), (II), (III-A), (III-B), (III-C), (III-D), (III-E ), (IV), (IV-A), (V), (VI), (VII), (VIII), (IX), (X), or (XI), or its pharmaceutical and a pharmaceutically acceptable carrier.

[0009] In another aspect, the disclosure provides therapeutically effective amounts of formulas (I), (II), (III-A), (III-B), (III-C), (III-D), (III-E ), (IV), (IV-A), (V), (VI), (VII), (VIII), (IX), (X), or (XI), or its pharmaceutical a second pharmacological agent; and a pharmaceutically acceptable carrier.

[0010] In another aspect, the disclosure provides therapeutically effective amounts of formulas (I), (II), (III-A), (III-B), (III-C), (III-D), (III-E ), (IV), (IV-A), (V), (VI), (VII), (VIII), (IX), (X), or (XI), or its pharmaceutical provides a method for treating or preventing a FAP-mediated condition by administering to a subject in need thereof a salt that is acceptable to FAP. In further embodiments, the FAP-mediated condition is selected from the group consisting of liver disease, type 2 diabetes, cardiovascular conditions, obesity, obesity-related conditions, fibrosis, keloid disorders, inflammation, and cancer. In a further embodiment, the FAP-mediated condition is a liver disease, particularly non-alcoholic steatohepatitis (NASH).

[0011] In another aspect, the present disclosure provides formulas (I), (II), (III-A), (III-B ), (III-C), (III-D), (III-E), (IV), (IV-A), (V), (VI), (VII), (VIII), (IX), A compound having the structure (X) or (XI), or a pharmaceutically acceptable salt thereof is provided.

[0012] In another aspect, the present disclosure provides formula (I), (II), (III-A), (III-B) for the preparation of a medicament for treating or preventing a FAP-mediated condition. , (III-C), (III-D), (III-E), (IV), (IV-A), (V), (VI), (VII), (VIII), (IX), ( The present invention provides the use of a compound having the structure X) or (XI), or a pharmaceutically acceptable salt thereof.

[0013] In another aspect, the present disclosure provides formulas (I), (II), (III-A), (III-B), (III-C), (III-D), (III-E), (IV ), (IV-A), (V), (VI), (VII), (VIII), (IX), (X), or (XI), or a pharmaceutically acceptable compound thereof Provide a kit containing salt.

[0014] In another aspect, the present disclosure provides formulas (I), (II), (III-A), (III-B), (III-C), (III-D), (III-E), (IV ), (IV-A), (V), (VI), (VII), (VIII), (IX), (X), or (XI), or a pharmaceutically acceptable compound thereof A method for preparing a salt is provided. [Details for carrying out the invention]

[0015] Many embodiments are described in detail throughout this specification and will be apparent to those skilled in the art. This specification should not be construed as limited to any particular embodiments described herein.

[0016] I. Definition With respect to the embodiments disclosed herein, the following terms have the following meanings:

[0017] References to "a" or "an" mean "one or more." Throughout, plural and singular forms should be treated interchangeably, except where indicated by number.

[0018] Unless the context requires otherwise, the words "comprise" or "comprises" or "comprising" shall be interpreted inclusively and not exclusively. , and used in Applicant's interpretation of this patent, including the following claims, on the basis and with the express understanding that each of those words is intended to be so interpreted. .

[0019] The term "halogen" (alone or in combination with another term) refers to a fluorine group (which may be indicated as -F), a chlorine group (which may be indicated as -Cl), a bromine group (which may be indicated as -Br), or Refers to an iodine group (which may be designated as -I).

[0020] The term "hydroxy" (alone or in combination with another term) means -OH.

[0021] The term "cyano" (alone or in combination with another term) means -CN.

[0022] The term "oxo" (alone or in combination with another term) means an oxo group and may be designated as =O.

[0023] The term "alkyl" (alone or in combination with another term) means a straight or branched chain saturated hydrocarbyl substituent (ie, a substituent containing only carbon and hydrogen). Alkyl typically has 1 to about 20 carbon atoms, more typically 1 to about 12 carbon atoms, even more typically 1 to about 8 carbon atoms, even more typically Typically, it contains from 1 to about 6 carbon atoms. Examples of such substituents include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, 2,2-dimethylpropyl, hexyl, heptyl. , and octyl.

[0024] The term "cycloalkyl" (alone or in combination with another term) refers to a group of from 3 to about 14 carbon ring atoms, more typically from 3 to about 12 carbon ring atoms, even more typically: Refers to a saturated carbocyclyl substituent containing from 3 to about 8 carbon ring atoms. Cycloalkyl typically contains a single carbocycle containing 3 to 6 carbon ring atoms. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0025] The term "cycloalkylalkyl" (alone or in combination with another term(s)) means alkyl substituted with cycloalkyl. Examples of such substituents include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, and cyclohexylmethyl.

[0026] The term "alkoxy" (alone or in combination with another term) means an alkyl ether substituent, ie, alkyl-O-. Examples of alkoxy include methoxy (CH 3 -O-), ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy. Therefore, for example, (i) The term "alkoxyalkyl" (alone or in combination with another term) means alkyl substituted with alkoxy, such as "methoxymethyl", which may be denoted as: [ka] ; (ii) The term "cycloalkylalkoxy" (alone or in combination with another term) means alkoxy substituted with cycloalkyl, such as "cyclopropylmethoxy", which may be represented as: [ka] ; (iii) The term "alkoxyalkoxy" (alone or in combination with another term) means alkoxy substituted with another alkoxy such as "methoxyethoxy" which may be denoted as: [ka] ; (iv) The term "alkoxyalkoxyalkyl" (alone or in combination with another term) means alkyl substituted with alkoxyalkoxy such as "methoxyethoxymethyl" which may be represented as: [ka] ; (v) The term "alkoxyphenyl" (alone or in combination with another term) means phenyl substituted with alkoxy, such as "4-methoxyphenyl", which may be represented as: [ka] ;as well as (vi) The term "alkoxyphenylalkyl" (alone or in combination with another term) means alkyl substituted with alkoxyphenyl, such as "4-methoxyphenylmethyl", which may be represented as: [ka] .

[0027] In some instances, the number of carbon atoms in a substituent (e.g., alkyl, cycloalkyl, etc.) is determined by the prefix "C x~y -", where x is the minimum number of carbon atoms in the substituent and y is the maximum number of carbon atoms in the substituent. So, for example, "C 1~6 "-Alkyl" refers to an alkyl substituent containing 1 to 6 carbon atoms. To further illustrate, C 3~6 -Cycloalkyl refers to a cycloalkyl substituent containing 3 to 6 carbon ring atoms.

[0028] The prefix "halo" indicates that the substituent to which it is prefixed is substituted with one or more independently selected halogen groups. For example, haloalkyl means an alkyl substituent in which at least one hydrogen group is replaced with a halogen group. When there are two or more hydrogens replaced by halogens, the halogens may be the same or different. Examples of haloalkyl are fluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, 1,1,1-trifluoroethyl, pentafluoroethyl, difluoropropyl, heptafluoropropyl, chloromethyl, dichloromethyl, trichloromethyl, difluoro Mention may be made of chloromethyl, dichlorofluoromethyl, and dichloropropyl. Similarly, "haloalkoxy" means an alkoxy substituent in which at least one hydrogen group is replaced with a halogen group. When there are two or more hydrogens replaced by halogens, the halogens may be the same or different. Examples of haloalkoxy substituents include fluoromethoxy, difluoromethoxy, trifluoromethoxy (also known as "perfluoromethyloxy"), 1,1,1-trifluoroethoxy, and chloromethoxy.

[0029] The term "carbonyl" (alone or in combination with another term) means -C(O)-, which may also be denoted as: [ka] . Therefore, for example, (i) The term "alkylcarbonyl" (alone or in combination with another term) may be denoted as "methylcarbonyl" (i.e. acetyl): [ka] ,and means alkyl-C(O)- such as ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, and other alkylcarbonyl substituents such as hexylcarbonyl; (ii) The term "alkylcarbonylalkyl" (alone or in combination with another term) means alkyl substituted with an alkylcarbonyl such as "methylcarbonylmethyl" which may be denoted as: [ka] ; (iii) The term "cycloalkylcarbonyl" (alone or in combination with another term) means cycloalkyl-C(O)-, such as "cyclopropylcarbonyl", which may be represented as: [ka] ;as well as (iv) the term "cycloalkylcarbonylalkyl" (alone or in combination with another term) means alkyl substituted with cycloalkylcarbonyl, such as "cyclopropylcarbonylmethyl", which may be denoted as [ka] .

[0030] The term "thio" or "thia" (alone or in combination with another term) means a divalent sulfur atom, which may also be designated -S-.

[0031] The term "sulfinyl" or "sulfoxide" (alone or in combination with another term) means -S(O)-, which may also be denoted as -S(O)-. [ka]

[0032] The term "sulfonyl" (alone or in combination with another term) may also be denoted as -S(O) 2 - means. [ka] Thus, for example, "alkylsulfonyl" (alone or in combination with another term) means alkyl-S(O) 2 - means. Examples of alkylsulfonyl substituents include methylsulfonyl, ethylsulfonyl, and propylsulfonyl. Similarly, the term "alkylsulfonylalkyl" (alone or in combination with another term) means alkyl substituted with alkylsulfonyl, such as "methylsulfonylmethyl", which may be denoted as: [ka] .

[0033] The term "alkylcarbonylaminoalkyl" (alone or in combination with another term) means alkyl-C(O)-N(H)-alkyl, such as "methylcarbonylaminomethyl", which may also be denoted as: [ka] .

[0034] The term "heterocyclyl" (alone or in combination with another term) means a saturated, partially saturated, or fully unsaturated (ie, heteroaryl) ring system containing a total of 3 to 14 ring atoms. At least one of the ring atoms is a heteroatom (ie, oxygen, nitrogen, or sulfur), and the remaining ring atoms are independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.

[0035] Heterocyclyl includes, for example, monocyclic saturated, partially unsaturated, and fully unsaturated ring structures having 3 to 7 members, such as 3 to 6 members, 5 to 7 members, such as 5 or 6 members, at least one member and up to 4 members of the ring, in particular 1, 2 or 3 members, are heteroatoms selected from N, O and S in stable combinations known to the person skilled in the art; The remaining ring atoms are carbon atoms. Examples of monocyclic heterocyclyls are furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, isopyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl. , triazolyl, tetrazolyl, dithiolyl, oxathiolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxathiazolyl, dioxazolyl, oxathiazolyl, oxathiolyl, oxathiolanyl, pyranyl, dihydropyranyl, pyridinyl, piperidinyl, Includes pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, triazinyl, oxazinyl, isoxazolidinyl, oxazolidinyl, isoxazolidinyl, oxathiazinyl, morpholinyl, azepinyl, oxepinyl, thiepinyl, and diazepinyl.

[0036] Heterocyclyl further includes bicyclic ring systems fused together (i.e., fused bicyclics) or bicyclic rings having only one shared atom (i.e., spiro), where at least one such ring , containing heteroatoms (ie, nitrogen, oxygen, or sulfur) as ring atoms. Examples of heterocyclyls having two ring structures fused together include indolizinyl, pyrindinyl, pyranopyrrolyl, 4H-quinolidinyl, purinyl, naphthyridinyl, pyridopyridinyl, pteridinyl, indolyl, isoindolyl, indoleninyl, isoindazolyl, benzazinyl, phthalazinyl, quinoxalinyl, Quinazolinyl, benzodiazinyl, benzopyranyl, benzothiopyranyl, benzoxazolyl, indoxadinyl, anthranilyl, benzodioxolyl, benzodioxanyl, benzoxadiazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, isobenzothienyl, benzothiazolyl , benzothiadiazolyl, benzimidazolyl, benzotriazolyl, benzoxazinyl, benzisoxazinyl, and tetrahydroisoquinolinyl.

[0037] A substituent is "substitutable" if it contains at least one carbon or nitrogen atom bonded to one or more hydrogen atoms. Thus, for example, hydrogen, halogen, and cyano are outside the scope of this definition.

[0038] When a substituent is described as "substituted," a non-hydrogen group is present in place of the group on a carbon or nitrogen of the substituent. Thus, for example, a substituted alkyl substituent is an alkyl substituent and at least one non-hydrogen group is present in place of a hydrogen group on the alkyl substituent. To illustrate, monofluoroalkyl is an alkyl substituted with one fluoro group and difluoroalkyl is an alkyl substituted with two fluoro groups. It should be recognized that when more than one substituent is present on a substituent, each non-hydrogen group may be the same or different (unless specified otherwise). be.

[0039] When a substituent is described as "optionally substituted," the substituent may be (1) unsubstituted or (2) substituted. When a carbon of a substituent is described as optionally substituted with one or more of the list of substituents, one or more of the hydrogens (if present) on the carbon, separately and / or together, , may be substituted with independently selected optional substituents. When a nitrogen of a substituent is described as being optionally substituted with one or more of the list of substituents, one or more of the hydrogens on the nitrogen (where present) are each independently selected. May be substituted with optional substituents.

[0040] When substituents are described as being "independently selected" from a group, each substituent is selected independently of the others. Therefore, each substituent may be the same as or different from other substituents.

[0041] The term "pharmaceutically acceptable" is used adjectively herein to mean that the modified noun is suitable for use as a pharmaceutical product or as part of a pharmaceutical product. For example, a "pharmaceutically acceptable salt" is a salt that is suitable for use in mammals, especially humans, and is an inorganic base, an organic base, an inorganic acid, an organic acid, or a salt suitable for use in mammals, especially humans. Includes salts with suitable basic or acidic amino acids.

[0042] A "therapeutically effective amount" of a pharmacological agent is an amount sufficient to produce a beneficial or desired result, including clinical results, and will therefore depend on the context in which it is being administered. If a pharmacological agent is being administered to treat a liver disease, for example, a therapeutically effective amount of the agent will produce an anti-liver disease effect in the subject compared to the response obtained without administration of the drug. The amount of drug alone or in combination with additional therapies that is sufficient to provide.

[0043] The term "prevent" can include preventing the onset of a disease, which is readily understood by a physician of ordinary skill and is intended to have its standard meaning with respect to the treatment of a particular medical condition. primary prevention, and secondary prevention in which the condition has already developed and the patient is temporarily or permanently protected against exacerbation or aggravation of the disease or the development of new symptoms related to the condition. .

[0044] The term "treat" is readily understood by a physician of ordinary skill in the art and refers to the treatment of a particular condition, including (1) reducing the extent or cause of the condition being treated, and / or (2) reducing the severity of the condition. It may include reducing or ameliorating one or more associated symptoms. Treatment of liver disease may include, for example, stabilizing (i.e., not worsening), slowing, or slowing, in whole or in part, the spread or progression of liver disease; in the absence of treatment; This may include prolonging survival as compared to expected survival; and / or otherwise ameliorating or alleviating the severity of cancer or liver disease.

[0045] II.Compound In one embodiment, the present disclosure provides compounds having the structure of formula (I): [ka] and a pharmaceutically acceptable salt thereof (wherein, X 1 are -S-, -S(O)-, and -S(O) 2 - selected from the group consisting of; R 1 is hydrogen, halogen, hydroxy, C 1~3 -alkyl, and C 1~6 - selected from the group consisting of alkoxy; R 2 teeth, (a) Heterocyclyl containing a total of 4 to 10 ring atoms (a heterocyclyl ring is: (i) a saturated, partially saturated, or fully unsaturated monocyclic or fused bicyclic ring; and (ii) 1 , 2, or 3 nitrogen ring atoms, the remaining ring atoms are carbon, and (iii) halogen, hydroxy, oxo, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 - optionally substituted with one or more substituents independently selected from the group consisting of alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl, and (a) C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 -alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl may be further substituted with one or more halogens, and (b) C 1~6 The alkyl may be further substituted with one or more hydroxy); (b) heterocyclyl containing a total of 5 to 10 ring atoms; a heterocyclyl ring is: (i) a saturated, partially saturated, or fully unsaturated monocyclic or fused bicyclic ring; and (ii) a) has one nitrogen ring atom and one oxygen ring atom, and the remaining ring atoms are carbon; or (b) has one nitrogen ring atom and one sulfur ring atom; the remaining ring atoms are carbon, and (iii) halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3-alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl may be further substituted with one or more halogens); and (c) a spiroheterocyclyl containing a total of 6 to 11 ring atoms; a spiroheterocyclyl: (i) contains two saturated rings; (ii) has (a) 1 or 2 nitrogen ring atoms; , the remaining ring atoms are carbon, or (b) have 1 or 2 nitrogen ring atoms and 1 or 2 oxygen ring atoms, and the remaining ring atoms are carbon, or (c) 1 nitrogen ring atoms and one sulfur ring atom, the remaining ring atoms are carbon, and (iii) halogen, oxo, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl) selected from the group consisting of; R 3 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl; R 4 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl; R 5 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl; and R 6 is hydrogen, halogen, and C 1~3 -alkyl).

[0046] In some embodiments, the present disclosure provides compounds having the structure of formula (II): [ka] and a pharmaceutically acceptable salt thereof (wherein X 1 ,R 1 ,R 2 ,R 3 ,R 4 ,R 5 , and R 6 is as defined above for compounds of formula (I)). In one aspect, X 1 is -S-. In another aspect, X 1 is -S(O)-. In another aspect, X 1 is -S(O) 2 -is.

[0047] In some embodiments, R 1 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl. In one aspect, R 1 is selected from the group consisting of hydrogen, chloro, fluoro, and methyl. In another aspect, R 1 is hydrogen. In another aspect, R 1 is chloro. In another aspect, R 1 is fluoro. In another aspect, R 1 is methyl.

[0048] In some embodiments, R 3 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl. In one aspect, R 3 is selected from the group consisting of hydrogen, chloro, fluoro, and methyl. In another aspect, R 3 is hydrogen. In another aspect, R 3 is chloro. In another aspect, R 3 is fluoro. In another aspect, R 3 is methyl.

[0049] In some embodiments, R 4 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl. In one aspect, R 4 is hydrogen. In another aspect, R 4 is chloro. In another aspect, R 4 is fluoro. In another aspect, R 4 is methyl.

[0050] In some embodiments, R 5 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl. In one aspect, R 5 is selected from the group consisting of hydrogen, chloro, fluoro, and methyl. In another aspect, R 5 is hydrogen. In another aspect, R 5 is fluoro. In another aspect, R 5 is chloro. In another aspect, R 5 is methyl.

[0051] In some embodiments, R 6 is hydrogen, halogen, and C 1~3 - selected from the group consisting of alkyl. In one aspect, R 6 is selected from the group consisting of hydrogen, chloro, fluoro, and methyl. In another aspect, R 6 is hydrogen. In another embodiment, R 6 is chloro. In another aspect, R 6 is fluoro. In another aspect, R 6 is methyl.

[0052] In some embodiments, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is halogen and C 1~3 - alkyl selected from the group consisting of the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In one aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is selected from the group consisting of chloro, fluoro, and methyl, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is selected from the group consisting of chloro and fluoro, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is chloro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is fluoro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is methyl and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen.

[0053] In some embodiments, R 1 ,R 3 ,R 4 ,R 5 , and R 6 At least two of the substituents are independently halogen and C 1~3 - alkyl selected from the group consisting of the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In one aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 Two of the substituents are independently selected from the group consisting of chloro, fluoro, and methyl, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen.

[0054] In some embodiments, R 1 ,R 3 ,R 4 ,R 5 , and R 6 At least one of the substituents is chloro.

[0055] In some embodiments, R 1 ,R 3 ,R 4 ,R 5 , and R 6 At least one of the substituents is fluoro.

[0056] In some embodiments, R 1 ,R 3 ,R 4 ,R 5 , and R 6 At least one of the substituents is methyl.

[0057] In some embodiments, the present disclosure provides compounds having the structure of formula (III-A): [ka] and its pharmaceutically acceptable salts (wherein R 1 and R 2 (as defined in the various embodiments above).

[0058] In some embodiments, the present disclosure provides compounds having the structure of formula (III-B): [ka] and its pharmaceutically acceptable salts (wherein R 2 and R 3 (as defined in the various embodiments above).

[0059] In some embodiments, the present disclosure provides compounds having the structure of formula (III-C): [ka] and its pharmaceutically acceptable salts (wherein R 2 and R 4 (as defined in the various embodiments above).

[0060] In some embodiments, the present disclosure provides compounds having the structure of formula (III-D): [ka] and its pharmaceutically acceptable salts (wherein R 2 and R 5 (as defined in the various embodiments above).

[0061] In some embodiments, the present disclosure provides compounds having the structure of formula (III-E): [ka] and its pharmaceutically acceptable salts (wherein R 2 and R 6 (as defined in the various embodiments above).

[0062] In some embodiments, the present disclosure provides a compound having the structure of formula (IV): [ka] and its pharmaceutically acceptable salts (wherein R 2 is as defined above for compounds of formula (I)).

[0063] In some embodiments, the present disclosure provides compounds having the structure of formula (IV-A): [ka] or a pharmaceutically acceptable salt thereof (wherein R 2 is as defined above for compounds of formula (I)).

[0064] A.R. 2 is a monocyclic or fused bicyclic heterocyclyl (nitrogen and carbon ring atoms) In some embodiments, the present disclosure provides formulas (I), (II), (III-A), (III-B), (III-C), (III-D), (III-E), A compound having the structure (IV) or (IV-A), and a pharmaceutically acceptable salt thereof (wherein R 2 is a heterocyclyl containing a total of 4 to 10 ring atoms, and the heterocyclyl ring is (i) a saturated, partially saturated, or fully unsaturated monocyclic or fused bicyclic ring; and (ii) has 1, 2, or 3 nitrogen ring atoms, the remaining ring atoms are carbon, and (iii) halogen, hydroxy, oxo, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 - optionally substituted with one or more substituents independently selected from the group consisting of alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl; C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 -alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl may be further substituted with one or more halogens, and (b) C 1~6 Alkyl may further be substituted with one or more hydroxy. In one aspect, R 2 A heterocyclyl ring is a saturated monocyclic ring. In another aspect, R 2 A heterocyclyl ring is a partially saturated monocyclic ring. In another aspect, R 2 A heterocyclyl ring is a fully unsaturated monocyclic ring. In another aspect, R 2 A heterocyclyl ring is a saturated fused bicyclic ring. In another aspect, R 2 A heterocyclyl ring is a partially saturated fused bicyclic ring. In another aspect, R 2 A heterocyclyl ring is a fully unsaturated fused bicyclic ring. In another aspect, R 2 A heterocyclyl ring has one nitrogen ring atom and the remaining ring atoms are carbon. In another aspect, R 2 A heterocyclyl ring has two nitrogen ring atoms and the remaining ring atoms are carbon. In another aspect, R 2 A heterocyclyl ring has three nitrogen ring atoms and the remaining ring atoms are carbon.

[0065] In some embodiments, R 2 The heterocyclyl ring is: [ka] selected from the group consisting of; Heterocyclyl rings include halogen, hydroxy, oxo, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3-alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 - optionally substituted with one or more substituents independently selected from the group consisting of alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl, and (a) C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 -alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl may be further substituted with one or more halogens, and (b) C 1~6 Alkyl may be further substituted with one or more hydroxy.

[0066] In some embodiments, R 2 The heterocyclyl ring is: [ka] selected from the group consisting of Heterocyclyl rings include halogen, hydroxy, oxo, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 - optionally substituted with one or more substituents independently selected from the group consisting of alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl, and (a) C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 -alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl may be further substituted with one or more halogens, and (b) C 1~6 Alkyl may be further substituted with one or more hydroxy.

[0067] In some embodiments, R 2 The heterocyclyl ring is: [ka] selected from the group consisting of; Heterocyclyl rings include halogen, hydroxy, oxo, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 - optionally substituted with one or more substituents independently selected from the group consisting of alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl, and (a) C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl, C 1~3 -alkoxyphenyl-C 1~3 -alkyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl may be further substituted with one or more halogens, and (b) C 1~6 Alkyl may be further substituted with one or more hydroxy.

[0068] In some embodiments, R 2 Heterocyclyl rings include halogen, hydroxy, oxo, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -alkyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl may be further substituted with one or more halogens.

[0069] In some embodiments, R 2 Heterocyclyl rings include halogen, hydroxy, oxo, C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0070] In some embodiments, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, and morpholinyl; May be substituted with halogen.

[0071] In some embodiments, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl; Nyl may be further substituted with one or more halogens.

[0072] In some embodiments, R 2 The heterocyclyl ring is optionally substituted with one or more halogens. In one aspect, R 2 The heterocyclyl ring is optionally substituted with one or more chloro. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more fluoro.

[0073] In some embodiments, R 2 The heterocyclyl ring is optionally substituted with one or more hydroxy.

[0074] In some embodiments, R 2 The heterocyclyl ring is optionally substituted with one or more oxo.

[0075] In some embodiments, R 2 The heterocyclyl ring is optionally substituted with one or more cyano.

[0076] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 - optionally substituted with alkyl, C 1~3 -Alkyl may be further substituted with one or more substituents independently selected from halogen and hydroxy.

[0077] In some embodiments, R 2 A heterocyclyl ring has one or more C 3~6 -cycloalkyl optionally substituted with C 3~6 -Cycloalkyl may be further substituted with one or more halogens.

[0078] In some embodiments, R 2 A heterocyclyl ring has one or more C 3~6 -cycloalkyl-C 1~3 - optionally substituted with alkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0079] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 - optionally substituted with alkoxy, C 1~3 -Alkoxy may be further substituted with one or more halogens.

[0080] In some embodiments, R 2 A heterocyclyl ring has one or more C 3~6 - optionally substituted with cycloalkoxy, C 3~6 -Cycloalkoxy may be further substituted with one or more halogens.

[0081] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 -alkoxy-C 1~3 - optionally substituted with alkyl, C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0082] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 -alkoxy-C 2~3 - optionally substituted with alkoxy, C 1~3 -alkoxy-C 2~3 -Alkoxy may be further substituted with one or more halogens.

[0083] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 - optionally substituted with alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0084] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 - optionally substituted with alkylcarbonyl, C 1~3 -Alkylcarbonyl may be further substituted with one or more halogens.

[0085] In some embodiments, R 2 A heterocyclyl ring has one or more C 3~6 -cycloalkylcarbonyl optionally substituted with C 3~6 -Cycloalkylcarbonyl may be further substituted with one or more halogens.

[0086] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 -alkyl-carbonylamino-C 1~3 - optionally substituted with alkyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0087] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 -alkylsulfonyl-C 1~3 - optionally substituted with alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0088] In some embodiments, R 2 Heterocyclyl rings include phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -alkyl, and C 1~3 -alkoxyphenyl-C 1~3 -alkyl, phenyl, tolyl, phenyl-C 1~3 -alkyl, and C 1~3 -alkoxyphenyl-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0089] In some embodiments, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, and morpholinyl; May be substituted with halogen.

[0090] In some embodiments, R2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl; Nyl may be further substituted with one or more halogens.

[0091] In some embodiments, R 2 Heterocyclyl rings include fluoro, hydroxy, oxo, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, trifluoropropyl, methoxy, One or more substituents independently selected from the group consisting of ethoxy, isopropoxy, difluoromethoxy, trifluoromethoxy, methoxymethyl, trifluoromethoxymethyl, methylcarbonylaminomethyl, methylsulfonylmethyl, morpholinyl, and tetrahydropyranyl optionally substituted with a group.

[0092] In some embodiments, R 2 The heterocyclyl ring is independently selected from the group consisting of fluoro, hydroxy, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, difluoropropyl, cyclopropyl, methoxy, trifluoromethoxy, ethoxy, and methoxymethyl. Optionally substituted with one or more substituents.

[0093] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -alkyl, and morpholinyl, optionally substituted with one or more substituents independently selected from the group consisting of 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tolyl, C 1~3 -alkoxyphenyl, phenyl-C 1~3 -Alkyl and morpholinyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more fluoro. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, trifluoropropyl, cyclopropyl, methoxy, ethoxy, Optionally substituted with one or more substituents independently selected from the group consisting of difluoromethoxy, trifluoromethoxy, trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, methylamidomethyl, methylsulfonylmethyl, and morpholinyl. be done. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, difluoropropyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoromethoxy Optionally substituted with one or more substituents independently selected from the group consisting of methyl, methoxymethyl, methylamidomethyl, and morpholinyl.

[0094] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethylazetidin-1-yl)-quinoline-4-carboxamide (Example 20 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoroazetidin-1-yl)quinoline-4-carboxamide (Example 21); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylazetidin-1-yl)-quinoline-4-carboxamide (Example 22 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-difluoroazetidin-1-yl)-quinoline-4-carboxamide (Example 23 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 24); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methylazetidin-1-yl)quinoline-4-carboxamide (Example 25); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 26); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)-3-methylazetidin-1-yl)quinoline-4-carboxamide (Example 27); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 28 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(methoxymethyl)-3-methyl-azetidin-1-yl)quinoline-4-carboxamide (Example 29); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3R)-3-methoxy-2-methyl-azetidin-1-yl)quinoline- 4-carboxamide (Example 30); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)quinoline-4-carboxamide (implemented) Example 31); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxyazetidin-1-yl)quinoline-4-carboxamide (Example 66); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 113 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-morpholinoazetidin-1-yl)-quinoline-4-carboxamide (Example 122); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-((trifluoromethoxy)methyl)-azetidin-1-yl)quinoline-4-carboxamide (Example 130); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methyl-3-(2,2,2-trifluoroethyl)-azetidine-1- yl)quinoline-4-carboxamide (Example 131); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(trifluoromethoxy)azetidin-1-yl)quinoline-4-carboxamide (Example 132 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2-difluoroethyl)-3-methyl-azetidin-1-yl)quinoline -4-carboxamide (Example 133); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-cyclopropyl-3-methylazetidin-1-yl)quinoline-4-carboxamide (implemented) Example 134); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethyl)-3-methyl-azetidin-1-yl)quinoline-4-carboxamide (Example 135); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethoxy)azetidin-1-yl)quinoline-4-carboxamide (Example 136) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethyl-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 137); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethyl-3-fluoroazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 138); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2-difluoropropyl)azetidin-1-yl)quinoline-4-carboxamide( Example 140); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(3,3,3-trifluoropropyl)azetidin-1-yl)quinoline-4 -Carboxamide (Example 142); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-(trifluoromethyl)-azetidin-1-yl)quinoline-4- Carboxamide (Example 143); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2-difluoroethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 144); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-cyclopropylazetidin-1-yl)-quinoline-4-carboxamide (Example 145) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2-fluoroethyl)azetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 146); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(1,1-difluoroethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 147); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-isopropylazetidin-1-yl)quinoline-4-carboxamide (Example 148); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 151); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethoxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 152); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethyl-3-hydroxyazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 154); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-(fluoromethyl)azetidin-1-yl)quinoline-4-carboxamide ( Example 157); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2,2-trifluoroethyl)azetidin-1-yl)quinoline-4 -Carboxamide (Example 158); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-difluoro-2-methylazetidin-1-yl)quinoline-4-carboxamide ( Example 159); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-hydroxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 165); (R)-6-(3-(acetamidomethyl)-3-methylazetidin-1-yl)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4-carboxamide (Example 181); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-phenylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 182); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(p-tolyl)azetidin-1-yl)quinoline-4-carboxamide (Example 183 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(4-fluorophenyl)azetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 185); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(m-tolyl)azetidin-1-yl)quinoline-4-carboxamide (Example 186 ); (R)-6-(3-(4-chlorobenzyl)azetidin-1-yl)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamide (implemented) Example 187); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methyl-3-((methylsulfonyl)-methyl)azetidin-1-yl)quinoline- 4-carboxamide (Example 188); and a pharmaceutically acceptable salt thereof.

[0095] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylazetidin-1-yl)-quinoline-4-carboxamide (Example 22 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 24); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)-3-methylazetidin-1-yl)quinoline-4-carboxamide (Example 27); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 28 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(methoxymethyl)-3-methyl-azetidin-1-yl)quinoline-4-carboxamide (Example 29); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3R)-3-methoxy-2-methyl-azetidin-1-yl)quinoline- 4-carboxamide (Example 30); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)quinoline-4-carboxamide (implemented) Example 31); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxyazetidin-1-yl)quinoline-4-carboxamide (Example 66); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 113 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethyl)-3-methyl-azetidin-1-yl)quinoline-4-carboxamide (Example 135); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethyl-3-fluoroazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 138); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2-difluoropropyl)azetidin-1-yl)quinoline-4-carboxamide( Example 140); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-(trifluoromethyl)-azetidin-1-yl)quinoline-4- Carboxamide (Example 143); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(1,1-difluoroethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 147); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 151); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethoxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 152); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-(fluoromethyl)azetidin-1-yl)quinoline-4-carboxamide ( Example 157); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-hydroxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 165); and a pharmaceutically acceptable salt thereof.

[0096] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, oxo, C 1~6 -alkyl, hydroxy-C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -alkyl, hydroxy-C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, C 1~3 -alkyl, hydroxy-C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -alkyl, hydroxy-C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more fluoro. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, hydroxymethyl, cyclopropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, and trifluoromethoxymethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, hydroxy, methyl, ethyl, fluoromethyl, hydroxymethyl, methoxy, and trifluoromethoxy.

[0097] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-difluoropyrrolidin-1-yl)-quinoline-4-carboxamide (Example 47) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 48) ; N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R,4S)-3,4-difluoropyrrolidin-1-yl)-quinoline-4- Carboxamide (Example 50); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-fluoropyrrolidin-1-yl)-quinoline-4-carboxamide (Example 51); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-fluoropyrrolidin-1-yl)-quinoline-4-carboxamide (Example 52); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 54); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-methylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 55); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(trifluoromethyl)pyrrolidin-1-yl)quinoline-4-carboxamide (Example 56); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 57) ; N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-methylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 65); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-methoxypyrrolidin-1-yl)-quinoline-4-carboxamide (Example 161); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-hydroxy-3-methylpyrrolidin-1-yl)quinoline-4-carboxamide (Example 167); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-hydroxy-3-methylpyrrolidin-1-yl)quinoline-4-carboxamide (Example 168); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((RS)-3-fluoro-3-methylpyrrolidin-1-yl)quinoline-4-carboxamide (Example 198); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-2-cyclopropylpyrrolidin-1-yl)quinoline-4-carboxamide isomer 1 (Example 199); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-2-cyclopropylpyrrolidin-1-yl)quinoline-4-carboxamide isomer 2 (Example 200); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methoxypyrrolidin-1-yl)-quinoline-4-carboxamide (Example 207); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-methylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 211); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(methoxymethyl)pyrrolidin-1-yl)quinoline-4-carboxamide( Example 212); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,4S)-3,4-difluoropyrrolidin-1-yl)quinoline-4-carboxamide (Example 213); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R,4R)-3,4-difluoropyrrolidin-1-yl)quinoline-4-carboxamide (Example 214); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-(hydroxymethyl)pyrrolidin-1-yl)quinoline-4-carboxamide( Example 220); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-(hydroxymethyl)pyrrolidin-1-yl)quinoline-4-carboxamide( Example 221); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((RS)-3,3-difluoro-4-hydroxy-pyrrolidin-1-yl)quinoline- 4-carboxamide (Example 224); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R*,4R*)-3,4-dimethylpyrrolidin-1-yl)quinoline-4 -Carboxamide isomer 1 (Example 225); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R*,4R*)-3,4-dimethylpyrrolidin-1-yl)quinoline-4 -Carboxamide isomer 2 (Example 226); and a pharmaceutically acceptable salt thereof.

[0098] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6-alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more fluoro. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, cyclopropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, Optionally substituted with one or more substituents independently selected from the group consisting of methoxymethyl, and trifluoromethoxymethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, hydroxy, methyl, ethyl, fluoromethyl, methoxy, and trifluoromethoxy.

[0099] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxopyrrolidin-1-yl)quinoline-4-carboxamide (Example 11); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethyl-2-oxopyrrolidin-1-yl)quinoline-4-carboxamide (implemented) Example 12); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopyrrolidin-1-yl)quinoline-4- Carboxamide isomer 1 (Example 201); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopyrrolidin-1-yl)quinoline-4- Carboxamide isomer 2 (Example 202); and a pharmaceutically acceptable salt thereof.

[0100] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, C 1~6 -alkyl, hydroxy-C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 C 1~6 -alkyl, hydroxy-C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkyl-carbonylamino-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, hydroxy, C 1~3 -Alkyl, C 3~6 -cycloalkyl, cyclopropyl-C 1~3 -Alkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -alkyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydrooxepanyl, 1~3 -Alkyl, C 3~6 -cycloalkyl, cyclopropyl-C 1~3 -Alkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -alkyl, and tetrahydropyranyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, cyclopropyl, cyclopropylmethyl, methoxy, ethoxy, trifluoromethoxy, Optionally substituted with one or more substituents independently selected from the group consisting of trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and tetrahydropyranyl. In another aspect, R 2 The heterocyclyl ring is independently selected from the group consisting of methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, cyclopropyl, and tetrahydropyranyl. Optionally substituted with one or more substituents.

[0101] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-methyl-1H-pyrazol-4-yl)-quinoline-4-carboxamide (Example 129 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-cyclopropyl-1H-pyrazol-4-yl)-quinoline-4-carboxamide (Example 170); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-quinoline-4-carboxamide (implemented) Example 171); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,5-dimethyl-1-(tetrahydro-2H-pyran-4-yl)-1H- Pyrazol-4-yl)quinoline-4-carboxamide (Example 172); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) Quinoline-4-carboxamide (Example 173); and a pharmaceutically acceptable salt thereof.

[0102] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl C 1~3 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl C 1~3 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3-alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl, phenyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, hydroxy, C 1~3 -Alkyl, C 3~6 -cycloalkyl, cyclopropyl-C 1~3 -Alkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -alkyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydroxepanyl, 1~3 -Alkyl, C 3~6 -cycloalkyl, cyclopropyl-C 1~3 -Alkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -alkyl, and tetrahydropyranyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include fluoro, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, cyclopropyl, methoxy, ethoxy, trifluoromethoxy, trifluoro Optionally substituted with one or more substituents independently selected from the group consisting of ethoxy, methoxymethyl, trifluoromethoxymethyl, and tetrahydropyranyl. In another aspect, R 2 The heterocyclyl ring is independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, cyclopropyl, and tetrahydropyranyl. optionally substituted with one or more substituents.

[0103] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-methyl-1H-pyrazol-5-yl)-quinoline-4-carboxamide (Example 174 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl) Quinoline-4-carboxamide (Example 176); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1H-pyrazol-5-yl)quinoline-4-carboxamide (Example 196); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-isopropyl-1H-pyrazol-5-yl)-quinoline-4-carboxamide (Example 197 ); and a pharmaceutically acceptable salt thereof.

[0104] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -alkyl, phenyl, tolyl, and C 1~3 -alkoxyphenyl optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -alkyl, phenyl, tolyl, and C 1~3 -Alkoxyphenyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, C 1~3 -Alkyl, cyclopropyl, cyclopropyl-C 1~3 -Alkyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, cyclopropyl, cyclopropyl-C 1~3 -Alkyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more fluoro. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclopropylmethyl, methoxy, ethoxy, propoxy, iso Optionally substituted with one or more substituents independently selected from the group consisting of propoxy, trifluoromethoxy, trifluoroethoxy, methoxymethyl, and trifluoromethoxymethyl. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, propoxy, isopropoxy, trifluoro Optionally substituted with one or more substituents independently selected from the group consisting of methoxy, and trifluoroethoxy.

[0105] In some embodiments, the compounds and pharmaceutically acceptable salts are N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,4S,5R)-4-hydroxy-3,5-dimethylpiperidin-1-yl )quinoline-4-carboxamide (Example 7); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-methoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 8); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(piperidin-1-yl)quinoline-4-carboxamide (Example 32); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,4-dimethylpiperidin-1-yl)-quinoline-4-carboxamide (Example 33) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoro-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 34 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,4-difluoropiperidin-1-yl)-quinoline-4-carboxamide (Example 35) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-difluoropiperidin-1-yl)-quinoline-4-carboxamide (Example 36) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-(fluoromethyl)-4-methyl-piperidin-1-yl)quinoline-4-carboxamide (Example 37); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,4-difluoro-3,3-dimethyl-piperidin-1-yl)quinoline-4- Carboxamide (Example 38); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-(trifluoromethyl)piperidin-1-yl)-quinoline-4-carboxamide (Example 39); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoropiperidin-1-yl)quinoline-4-carboxamide (Example 40); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 41); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-methoxy-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 42 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-isopropoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 43); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,4-difluoro-2-methylpiperidin-1-yl)quinoline-4-carboxamide (implemented) Example 44); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(fluoromethyl)piperidin-1-yl)quinoline-4-carboxamide( Example 45); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-ethyl-4-hydroxypiperidin-1-yl)quinoline-4-carboxamide (Example 189 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-hydroxy-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 190 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-ethyl-4-methoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 191); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-hydroxy-4-isopropylpiperidin-1-yl)quinoline-4-carboxamide (Example 192 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R,4S,5S)-4-hydroxy-3,4,5-trimethylpiperidine-1 -yl)quinoline-4-carboxamide (Example 193); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoropiperidin-1-yl)quinoline-4-carboxamide (Example 205); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoro-4-phenylpiperidin-1-yl)-quinoline-4-carboxamide (Example 223); and a pharmaceutically acceptable salt thereof.

[0106] In some embodiments, R 2 The heterocyclyl ring is: [ka] It is.

[0107] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-oxopiperidine -1-yl)quinoline-4-carboxamide (Example 230), or a pharmaceutically acceptable salt thereof.

[0108] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -cycloalkylcarbonyl, and phenyl, optionally substituted with one or more substituents independently selected from the group consisting of 1~6 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl, C 3~6 -Cycloalkylcarbonyl and phenyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, oxo, C 1~3 -Alkyl, cyclopropyl, cyclopropyl-C 1~3 -Alkyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, cyclopropyl, cyclopropyl-C 1~3 -Alkyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more fluoro. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, oxo, methyl, ethyl, isopropyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclopropylmethyl, methoxy, ethoxy, propoxy , trifluoromethoxy, trifluoroethoxy, methoxymethyl, and trifluoromethoxymethyl. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, oxo, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, trifluoromethoxy, tri Optionally substituted with one or more substituents independently selected from the group consisting of fluoroethoxy, and methoxymethyl.

[0109] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoro- 1-methylpiperidin-4-yl)quinoline-4-carboxamide (Example 195), or a pharmaceutically acceptable salt thereof.

[0110] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, and C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, and C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more fluoro. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, propoxy, isopropoxy, trifluoro Optionally substituted with one or more substituents independently selected from the group consisting of methoxy, trifluoroethoxy, methoxymethyl, and trifluoromethoxymethyl. In another aspect, R 2Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, isopropoxy, trifluoromethoxy, Optionally substituted with one or more substituents independently selected from the group consisting of trifluoroethoxy, and methoxymethyl.

[0111] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxopiperidin-1-yl)quinoline-4-carboxamide (Example 14); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethyl-2-oxopiperidin-1-yl)-quinoline-4-carboxamide( Example 15); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopiperidin-1-yl)quinoline-4- Carboxamide isomer 1 (Example 203); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopiperidin-1-yl)quinoline-4- Carboxamide isomer 2 (Example 204); and a pharmaceutically acceptable salt thereof.

[0112] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, C 1~6 -alkyl, hydroxy-C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkyloxy, and C 1~3 -alkoxy-C 2~3 -alkyloxy-C 1~3 optionally substituted with one or more substituents independently selected from the group consisting of alkyl; 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkyloxy, and C 1~3 -alkoxy-C 2~3 -alkyloxy-C 1~3 Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, C 1~3 -alkyl, hydroxy-C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more fluoro. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, propoxy, trifluoromethoxy, Optionally substituted with one or more substituents independently selected from the group consisting of trifluoroethoxy, methoxymethyl, and trifluoromethoxymethyl. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, and Optionally substituted with one or more substituents independently selected from the group consisting of methoxymethyl.

[0113] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(pyridin-3-yl)quinoline-4-carboxamide (Example 126); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-methylpyridin-3-yl)quinoline-4-carboxamide (Example 128); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-(difluoromethyl)pyridin-3-yl)-quinoline-4-carboxamide (Example 169 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-methylpyridin-3-yl)quinoline-4-carboxamide (Example 177); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-methoxypyridin-3-yl)quinoline-4-carboxamide (Example 178); and a pharmaceutically acceptable salt thereof.

[0114] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, C 1~6 -alkyl, hydroxy-C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, and C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, and C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, C 1~3 -alkyl, hydroxy-C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more fluoro. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, propoxy, trifluoromethoxy, Optionally substituted with one or more substituents independently selected from the group consisting of trifluoroethoxy, methoxymethyl, and trifluoromethoxymethyl. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, and Optionally substituted with one or more substituents independently selected from the group consisting of methoxymethyl.

[0115] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,5- Dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-4-carboxamide (Example 123), or a pharmaceutically acceptable salt thereof.

[0116] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, hydroxy, C 1~6 -alkyl, hydroxy-C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, and C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -alkoxy, and C 1~3 -alkoxy-C 2~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, C 1~3 -alkyl, hydroxy-C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -alkyl, cyclopropyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more fluoro. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, propoxy, trifluoromethoxy, Optionally substituted with one or more substituents independently selected from the group consisting of trifluoroethoxy, methoxymethyl, and trifluoromethoxymethyl. In another aspect, R 2 Heterocyclyl rings include fluoro, hydroxy, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, cyclopropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, and Optionally substituted with one or more substituents independently selected from the group consisting of methoxymethyl.

[0117] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,6, 7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)quinoline-4-carboxamide (Example 175), or a pharmaceutically acceptable salt thereof.

[0118] In some embodiments, the compounds and pharmaceutically acceptable salts are N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,4S,5R)-4-hydroxy-3,5-dimethylpiperidin-1-yl )quinoline-4-carboxamide (Example 7); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-methoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 8); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxopyrrolidin-1-yl)quinoline-4-carboxamide (Example 11); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethyl-2-oxopyrrolidin-1-yl)quinoline-4-carboxamide (implemented) Example 12); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxopiperidin-1-yl)quinoline-4-carboxamide (Example 14); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethyl-2-oxopiperidin-1-yl)-quinoline-4-carboxamide( Example 15); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethylazetidin-1-yl)-quinoline-4-carboxamide (Example 20 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoroazetidin-1-yl)quinoline-4-carboxamide (Example 21); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylazetidin-1-yl)-quinoline-4-carboxamide (Example 22 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-difluoroazetidin-1-yl)-quinoline-4-carboxamide (Example 23 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 24); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methylazetidin-1-yl)quinoline-4-carboxamide (Example 25); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 26); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)-3-methylazetidin-1-yl)quinoline-4-carboxamide (Example 27); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 28 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(methoxymethyl)-3-methyl-azetidin-1-yl)quinoline-4-carboxamide (Example 29); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3R)-3-methoxy-2-methyl-azetidin-1-yl)quinoline- 4-carboxamide (Example 30); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)quinoline-4-carboxamide (implemented) Example 31); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(piperidin-1-yl)quinoline-4-carboxamide (Example 32); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,4-dimethylpiperidin-1-yl)-quinoline-4-carboxamide (Example 33) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoro-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 34 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,4-difluoropiperidin-1-yl)-quinoline-4-carboxamide (Example 35) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-difluoropiperidin-1-yl)-quinoline-4-carboxamide (Example 36) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-(fluoromethyl)-4-methyl-piperidin-1-yl)quinoline-4-carboxamide (Example 37); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,4-difluoro-3,3-dimethyl-piperidin-1-yl)quinoline-4- Carboxamide (Example 38); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-(trifluoromethyl)piperidin-1-yl)-quinoline-4-carboxamide (Example 39); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoropiperidin-1-yl)quinoline-4-carboxamide (Example 40); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 41); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-methoxy-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 42 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-isopropoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 43); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,4-difluoro-2-methylpiperidin-1-yl)quinoline-4-carboxamide (implemented) Example 44); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(fluoromethyl)piperidin-1-yl)quinoline-4-carboxamide( Example 45); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-difluoropyrrolidin-1-yl)-quinoline-4-carboxamide (Example 47) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 48) ; N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R,4S)-3,4-difluoropyrrolidin-1-yl)quinoline-4-carboxamide (Example 50); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-fluoropyrrolidin-1-yl)-quinoline-4-carboxamide (Example 51); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-fluoropyrrolidin-1-yl)-quinoline-4-carboxamide (Example 52); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)quinoline-4-carboxamide( Example 53); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 54); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-methylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 55); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(trifluoromethyl)pyrrolidin-1-yl)quinoline-4-carboxamide (Example 56); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 57) ; N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-fluoroazepan-1-yl)quinoline-4-carboxamide (Example 59); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-fluoroazepan-1-yl)quinoline-4-carboxamide (Example 60); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-methylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 65); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxyazetidin-1-yl)quinoline-4-carboxamide (Example 66); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 113 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,5,6,7-tetrahydro-1H-indazol-1-yl)quinoline-4- Carboxamide (Example 114); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,5,6,7-tetrahydro-2H-indazol-2-yl)quinoline-4- Carboxamide (Example 115); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)quinoline- 4-carboxamide (Example 116); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6,6-dimethyl-5,6-dihydrocyclopenta[c]pyrazole-2(4H) -yl)quinoline-4-carboxamide (Example 117); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(trifluoromethyl)-1H-pyrazol-1-yl)quinoline-4-carboxamide ( Example 118); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,6-difluoro-1H-indol-1-yl)-quinoline-4-carboxamide (implemented) Example 119); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5-fluoro-1H-indol-1-yl)quinoline-4-carboxamide (Example 120) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methyl-1H-pyrrol-1-yl)-quinoline-4-carboxamide (Example 121 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-morpholinoazetidin-1-yl)-quinoline-4-carboxamide (Example 122); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b] Pyrazol-3-yl)quinoline-4-carboxamide (Example 123); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-fluoropyridin-4-yl)quinoline-4-carboxamide (Example 124); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5-fluoropyridin-2-yl)quinoline-4-carboxamide (Example 125); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(pyridin-3-yl)quinoline-4-carboxamide (Example 126); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(pyrimidin-5-yl)quinoline-4-carboxamide (Example 127); R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-methylpyridin-3-yl)quinoline-4-carboxamide (Example 128); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-methyl-1H-pyrazol-4-yl)-quinoline-4-carboxamide (Example 129 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-((trifluoromethoxy)methyl)-azetidin-1-yl)quinoline-4-carboxamide (Example 130); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methyl-3-(2,2,2-trifluoroethyl)-azetidine-1- yl)quinoline-4-carboxamide (Example 131); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(trifluoromethoxy)azetidin-1-yl)quinoline-4-carboxamide (Example 132 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2-difluoroethyl)-3-methyl-azetidin-1-yl)quinoline -4-carboxamide (Example 133); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-cyclopropyl-3-methylazetidin-1-yl)quinoline-4-carboxamide (implemented) Example 134); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethyl)-3-methyl-azetidin-1-yl)quinoline-4-carboxamide (Example 135); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethoxy)azetidin-1-yl)-quinoline-4-carboxamide (Example 136 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethyl-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 137); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethyl-3-fluoroazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 138); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2-difluoropropyl)azetidin-1-yl)quinoline-4-carboxamide( Example 140); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(3,3,3-trifluoropropyl)azetidin-1-yl)quinoline-4 -Carboxamide (Example 142); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-(trifluoromethyl)-azetidin-1-yl)quinoline-4- Carboxamide (Example 143); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2-difluoroethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 144); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-cyclopropylazetidin-1-yl)-quinoline-4-carboxamide (Example 145) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2-fluoroethyl)azetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 146); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(1,1-difluoroethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 147); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-isopropylazetidin-1-yl)quinoline-4-carboxamide (Example 148); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 151); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethoxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 152); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethyl-3-hydroxyazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 154); 6-(6-azabicyclo[3.2.0]heptan-6-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamide (implemented) Example 156); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-(fluoromethyl)azetidin-1-yl)quinoline-4-carboxamide ( Example 157); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2,2-trifluoroethyl)azetidin-1-yl)quinoline-4 -carboxamide (Example 158); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-difluoro-2-methylazetidin-1-yl)quinoline-4-carboxamide ( Example 159); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6,6-difluoro-3-azabicyclo[3.1.0]hexan-3-yl)quinoline- 4-carboxamide (Example 160); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-methoxypyrrolidin-1-yl)-quinoline-4-carboxamide (Example 161); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-hydroxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 165); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-hydroxy-3-methylpyrrolidin-1-yl)quinoline-4-carboxamide (Example 167); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-hydroxy-3-methylpyrrolidin-1-yl)quinoline-4-carboxamide (Example 168); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-(difluoromethyl)pyridin-3-yl)-quinoline-4-carboxamide (Example 169 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-cyclopropyl-1H-pyrazol-4-yl)-quinoline-4-carboxamide (Example 170); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-quinoline-4-carboxamide (implemented) Example 171); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,5-dimethyl-1-(tetrahydro-2H-pyran-4-yl)-1H- Pyrazol-4-yl)quinoline-4-carboxamide (Example 172); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) Quinoline-4-carboxamide (Example 173); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-methyl-1H-pyrazol-5-yl)-quinoline-4-carboxamide (Example 174 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,6,7,8-tetrahydroimidazo[1,2-a]-pyridine-3- yl)quinoline-4-carboxamide (Example 175); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl) Quinoline-4-carboxamide (Example 176); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-methylpyridin-3-yl)quinoline-4-carboxamide (Example 177); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-methoxypyridin-3-yl)quinoline-4-carboxamide (Example 178); (R)-6-(3-(acetamidomethyl)-3-methylazetidin-1-yl)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4-carboxamide (Example 181); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-phenylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 182); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(p-tolyl)azetidin-1-yl)quinoline-4-carboxamide (Example 183 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(4-fluorophenyl)azetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 185); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(m-tolyl)azetidin-1-yl)quinoline-4-carboxamide (Example 186 ); (R)-6-(3-(4-chlorobenzyl)azetidin-1-yl)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamide (implemented) Example 187); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methyl-3-((methylsulfonyl)-methyl)azetidin-1-yl)quinoline- 4-carboxamide (Example 188); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-ethyl-4-hydroxypiperidin-1-yl)-quinoline-4-carboxamide (Example 189); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-hydroxy-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 190 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-ethyl-4-methoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 191); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-hydroxy-4-isopropylpiperidin-1-yl)quinoline-4-carboxamide (Example 192 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R,4S,5S)-4-hydroxy-3,4,5-trimethylpiperidine-1 -yl)quinoline-4-carboxamide (Example 193); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoro-1-methylpiperidin-4-yl)-quinoline-4-carboxamide (Example 195); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1H-pyrazol-5-yl)quinoline-4-carboxamide (Example 196); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-isopropyl-1H-pyrazol-5-yl)-quinoline-4-carboxamide (Example 197 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((RS)-3-fluoro-3-methylpyrrolidin-1-yl)quinoline-4-carboxamide (Example 198); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-2-cyclopropylpyrrolidin-1-yl)quinoline-4-carboxamide isomer 1 (Example 199); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-2-cyclopropylpyrrolidin-1-yl)quinoline-4-carboxamide isomer 2 (Example 200); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopyrrolidin-1-yl)quinoline-4- Carboxamide isomer 1 (Example 201); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopyrrolidin-1-yl)quinoline-4- Carboxamide isomer 2 (Example 202); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopiperidin-1-yl)quinoline-4- Carboxamide isomer 1 (Example 203); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopiperidin-1-yl)quinoline-4- Carboxamide isomer 2 (Example 204); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoropiperidin-1-yl)quinoline-4-carboxamide (Example 205); 6-(3-azabicyclo[3.1.0]hexan-3-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamide (implemented) Example 206); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methoxypyrrolidin-1-yl)-quinoline-4-carboxamide (Example 207); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((1R,5S,6R)-6-(trifluoromethyl)-3-azabicyclo[3.1. 0]hexan-3-yl)quinoline-4-carboxamide (Example 208); (R)-6-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamide (implemented) Example 209); 6-(2-azabicyclo[2.2.1]heptan-2-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamide (implemented) Example 210); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-methylpyrrolidin-1-yl)-quinoline-4-carboxamide (Example 211); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(methoxymethyl)pyrrolidin-1-yl)quinoline-4-carboxamide( Example 212); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,4S)-3,4-difluoropyrrolidin-1-yl)quinoline-4-carboxamide (Example 213); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R,4R)-3,4-difluoropyrrolidin-1-yl)quinoline-4-carboxamide (Example 214); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-phenyl-1H-imidazol-1-yl)-quinoline-4-carboxamide (Example 217 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-phenyl-1H-pyrrol-1-yl)-quinoline-4-carboxamide (Example 218 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4,5,6,7-tetrahydro-1H-indol-1-yl)quinoline-4- Carboxamide (Example 219); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-(hydroxymethyl)pyrrolidin-1-yl)quinoline-4-carboxamide( Example 220); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-(hydroxymethyl)pyrrolidin-1-yl)quinoline-4-carboxamide( Example 221); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoro-4-phenylpiperidin-1-yl)-quinoline-4-carboxamide (Example 223); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((RS)-3,3-difluoro-4-hydroxy-pyrrolidin-1-yl)quinoline- 4-carboxamide (Example 224); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R*,4R*)-3,4-dimethylpyrrolidin-1-yl)quinoline-4 -Carboxamide isomer 1 (Example 225); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R*,4R*)-3,4-dimethylpyrrolidin-1-yl)quinoline-4 -Carboxamide isomer 2 (Example 226); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-oxopiperidin-1-yl)quinoline-4-carboxamide (Example 230); and a pharmaceutically acceptable salt thereof.

[0119] In some embodiments, the compounds and pharmaceutically acceptable salts are N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,4S,5R)-4-hydroxy-3,5-dimethylpiperidin-1-yl )quinoline-4-carboxamide (Example 7); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-methoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 8); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethyl-2-oxopyrrolidin-1-yl)quinoline-4-carboxamide (implemented) Example 12); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethyl-2-oxopiperidin-1-yl)quinoline-4-carboxamide (implemented) Example 15); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylazetidin-1-yl)-quinoline-4-carboxamide (Example 22 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 24); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)-3-methylazetidin-1-yl)quinoline-4-carboxamide (Example 27); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethyl)azetidin-1-yl)quinoline-4-carboxamide (Example 28) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(methoxymethyl)-3-methyl-azetidin-1-yl)quinoline-4-carboxamide (Example 29); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3R)-3-methoxy-2-methyl-azetidin-1-yl)quinoline- 4-carboxamide (Example 30); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)quinoline-4-carboxamide (implemented) Example 31); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(piperidin-1-yl)quinoline-4-carboxamide (Example 32); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoro-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 34 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 41); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-methoxy-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 42 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-isopropoxypiperidin-1-yl)-quinoline-4-carboxamide (Example 43); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R,4S)-3,4-difluoropyrrolidin-1-yl)quinoline-4-carboxamide (Example 50); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-fluoropyrrolidin-1-yl)-quinoline-4-carboxamide (Example 52); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxyazetidin-1-yl)quinoline-4-carboxamide (Example 66); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)azetidin-1-yl)-quinoline-4-carboxamide (Example 113 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(difluoromethyl)-3-methyl-azetidin-1-yl)quinoline-4-carboxamide (Example 135); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethyl-3-fluoroazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 138); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(2,2-difluoropropyl)azetidin-1-yl)quinoline-4-carboxamide( Example 140); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-(trifluoromethyl)-azetidin-1-yl)quinoline-4- Carboxamide (Example 143); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(1,1-difluoroethyl)azetidin-1-yl)quinoline-4-carboxamide( Example 147); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxy-3-methylazetidin-1-yl)quinoline-4-carboxamide (Example 151); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-ethoxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 152); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-fluoro-3-(fluoromethyl)azetidin-1-yl)quinoline-4-carboxamide ( Example 157); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-methoxypyrrolidin-1-yl)-quinoline-4-carboxamide (Example 161); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-hydroxy-3-methylazetidin-1-yl)-quinoline-4-carboxamide (implemented) Example 165); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-(difluoromethyl)pyridin-3-yl)-quinoline-4-carboxamide (Example 169 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,5-dimethyl-1-(tetrahydro-2H-pyran-4-yl)-1H- Pyrazol-4-yl)quinoline-4-carboxamide (Example 172); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl )quinoline-4-carboxamide (Example 175); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-ethyl-4-hydroxypiperidin-1-yl)quinoline-4-carboxamide (Example 189 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-hydroxy-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 190 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoro-1-methylpiperidin-4-yl)-quinoline-4-carboxamide (Example 195); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((RS)-3-fluoro-3-methylpyrrolidin-1-yl)quinoline-4-carboxamide (Example 198); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopyrrolidin-1-yl)quinoline-4- Carboxamide isomer 1 (Example 201); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopyrrolidin-1-yl)quinoline-4- Carboxamide isomer 2 (Example 202); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopiperidin-1-yl)quinoline-4- Carboxamide isomer 1 (Example 203); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-methyl-2-oxopiperidin-1-yl)quinoline-4- Carboxamide isomer 2 (Example 204); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoropiperidin-1-yl)quinoline-4-carboxamide (Example 205); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methoxypyrrolidin-1-yl)-quinoline-4-carboxamide (Example 207); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,4S)-3,4-difluoropyrrolidin-1-yl)quinoline-4-carboxamide (Example 213); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-(hydroxymethyl)pyrrolidin-1-yl)quinoline-4-carboxamide( Example 221); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((RS)-3,3-difluoro-4-hydroxy-pyrrolidin-1-yl)quinoline- 4-carboxamide (Example 224); and a pharmaceutically acceptable salt thereof.

[0120] B.R. 2 is a monocyclic or fused bicyclic heterocyclyl (nitrogen, oxygen (or sulfur), and carbon ring atoms) In some embodiments, the present disclosure provides formulas (I), (II), (III-A), (III-B), (III-C), (III-D), (III-E), A compound having the structure (IV) or (IV-A), and a pharmaceutically acceptable salt thereof (wherein R 2 is a heterocyclyl containing a total of 5 to 10 ring atoms, and the heterocyclyl ring is (i) a saturated, partially saturated, or fully unsaturated monocyclic or fused bicyclic ring; (ii) (a) has one nitrogen ring atom and one oxygen ring atom and the remaining ring atoms are carbon; or (b) has one nitrogen ring atom and one sulfur ring atom. , the remaining ring atoms are carbon, and (iii) halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 A heterocyclyl ring is a saturated monocyclic ring. In another aspect, R 2 A heterocyclyl ring is a partially saturated monocyclic ring. In another aspect, R 2 A heterocyclyl ring is a fully unsaturated monocyclic ring. In another aspect, R 2 A heterocyclyl ring is a saturated fused bicyclic ring. In another aspect, R 2 A heterocyclyl ring is a partially saturated fused bicyclic ring. In another aspect, R 2 A heterocyclyl ring is a fully unsaturated fused bicyclic ring. In another aspect, R 2 A heterocyclyl ring has one nitrogen ring atom and one oxygen ring atom, and the remaining ring atoms are carbon. In another aspect, R 2A heterocyclyl ring has one nitrogen ring atom and one sulfur ring atom, and the remaining ring atoms are carbon.

[0121] In some embodiments, R 2 Heterocyclyl rings contain a total of 6 to 10 ring atoms.

[0122] In some embodiments, R 2 The heterocyclyl ring is: [ka] selected from the group consisting of; Heterocyclyl rings include halogen, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0123] In some embodiments, R 2 The heterocyclyl ring is: [ka] selected from the group consisting of; Heterocyclyl rings include halogen, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0124] In some embodiments, R 2 The heterocyclyl ring is: [ka] selected from the group consisting of; Heterocyclyl rings include halogen, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0125] In some embodiments, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~5 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -Alkyl, C 3~5 -cycloalkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0126] In some embodiments, R 2 Heterocyclyl rings include halogen, cyano, C 1~2 -Alkyl, C 3~4 -cycloalkyl, C 1~2 -alkoxy, C 1~2 -alkoxy-C 1~3 -Alkyl, C 1~2 -alkylcarbonyl-C 1~2 -alkyl, and C 1~2 -alkylsulfonyl-C 1~2 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~2 -Alkyl, C 3~4 -cycloalkyl, C 1~2 -alkoxy, C 1~2 -alkoxy-C 1~2 -Alkyl, C 1~2 -alkylcarbonyl-C 1~2 -alkyl, and C 1~2 -alkylsulfonyl-C 1~2 -Alkyl may be further substituted with one or more halogens.

[0127] In some embodiments, R 2 The heterocyclyl ring is optionally substituted with one or more halogens. In one aspect, R 2 The heterocyclyl ring is optionally substituted with one or more fluoro.

[0128] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 - optionally substituted with alkyl, C 1~3 -Alkyl may be further substituted with one or more halogens.

[0129] In some embodiments, R 2 A heterocyclyl ring has one or more C 3~6 -cycloalkyl optionally substituted with C 3~6 -Cycloalkyl may be further substituted with one or more halogens.

[0130] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 -alkoxy-C 1~3 - optionally substituted with alkyl, C 1~3 -alkoxy-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0131] In some embodiments, R 2 A heterocyclyl ring has one or more C 1~3 -alkylsulfonyl-C 1~3 - optionally substituted with alkyl, C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens.

[0132] In some embodiments, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, isopropoxy, Optionally substituted with one or more substituents independently selected from the group consisting of trifluoromethoxy, trifluoroethoxy, methoxymethyl, methoxyethyl, trifluoromethoxymethyl, and methylsulfonylmethyl.

[0133] In some embodiments, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, isopropyl, cyclopropyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy. .

[0134] In some embodiments, R 2 The heterocyclyl ring is: [ka] and R 2 Heterocyclyl rings include halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~5 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~5 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include fluoro, cyano, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, methoxyethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, trifluoromethyl, difluoropropyl, methoxy, trifluoromethoxy, and methoxymethyl. be done.

[0135] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-3-fluoro-6-morpholinoquinoline-4-carboxamide (Example 2); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-difluoromorpholino)quinoline-4-carboxamide (Example 4); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2,6,6-tetrafluoromorpholino)-quinoline-4-carboxamide (Example 5 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-8-methyl-6-morpholinoquinoline-4-carboxamide (Example 9); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-7-methyl-6-morpholinoquinoline-4-carboxamide (Example 10); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethyl-3-oxomorpholino)-quinoline-4-carboxamide (Example 16) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 67); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6S)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 68); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-(fluoromethyl)morpholino)-quinoline-4-carboxamide (Example 69 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6R)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 70); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(fluoromethyl)morpholino)-quinoline-4-carboxamide (Example 71 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-methylmorpholino)-quinoline-4-carboxamide (Example 72); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-(trifluoromethyl)-morpholino)quinoline-4-carboxamide (Example 73); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(trifluoromethyl)-morpholino)quinoline-4-carboxamide (Example 74); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,6S)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 78); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-methylmorpholino)-quinoline-4-carboxamide (Example 80); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3S)-2,3-dimethyl-morpholino)quinoline-4-carboxamide (Example 81); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3S)-2,3-dimethylmorpholino)quinoline-4-carboxamide (Example 82 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3R)-2,3-dimethyl-morpholino)quinoline-4-carboxamide (Example 83); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-(trifluoromethyl)-morpholino)quinoline-4-carboxamide isomer 1 (Example 84); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-(trifluoromethyl)-morpholino)quinoline-4-carboxamide isomer 2 (Example 85); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,5R)-2,5-dimethylmorpholino)quinoline-4-carboxamide (Example 87 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethylmorpholino)-quinoline-4-carboxamide (Example 88); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-(methoxymethyl)-morpholino)quinoline-4-carboxamide (Example 89 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,5R)-3,5-dimethyl-morpholino)quinoline-4-carboxamide (Example 90); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-((methylsulfonyl)-methyl)morpholino)quinoline-4-carboxamide( Example 92); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(methoxymethyl)-morpholino)quinoline-4-carboxamide (Example 93 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-((methylsulfonyl)-methyl)morpholino)quinoline-4-carboxamide( Example 94); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-(2-methoxyethyl)-morpholino)quinoline-4-carboxamide (implemented) Example 95); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3S)-3-(methoxymethyl)-2-methylmorpholino)quinoline-4- Carboxamide (Example 96); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3R)-3-(methoxymethyl)-2-methylmorpholino)quinoline-4- Carboxamide (Example 97); 7-bromo-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,5R)-3,5-dimethylmorpholino)quinoline-4-carboxamide (Example 100); (R)-5-chloro-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 101); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methylmorpholino)-quinoline-4-carboxamide (Example 102); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,5S)-3,5-dimethylmorpholino)-quinoline-4-carboxamide (Example 103); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R,5R)-3,5-dimethylmorpholino)-quinoline-4-carboxamide (Example 105); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-ethylmorpholino)quinoline-4-carboxamide (Example 106); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 107); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-methylmorpholino)-quinoline-4-carboxamide (Example 108); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-2-methyl-6-morpholinoquinoline-4-carboxamide (Example 109); (R)-7-chloro-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 179); (R)-8-chloro-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 180); and a pharmaceutically acceptable salt thereof.

[0136] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-8-methyl-6-morpholinoquinoline-4-carboxamide (Example 9); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 67); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6S)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 68); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-(fluoromethyl)morpholino)-quinoline-4-carboxamide (Example 69 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6R)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 70); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(fluoromethyl)morpholino)-quinoline-4-carboxamide (Example 71 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-methylmorpholino)-quinoline-4-carboxamide (Example 72); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-(trifluoromethyl)-morpholino)quinoline-4-carboxamide (Example 73); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(trifluoromethyl)-morpholino)quinoline-4-carboxamide (Example 74); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,6S)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 78); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-methylmorpholino)-quinoline-4-carboxamide (Example 80); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3S)-2,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 81); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3S)-2,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 82); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethylmorpholino)-quinoline-4-carboxamide (Example 88); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-(methoxymethyl)-morpholino)quinoline-4-carboxamide (Example 89 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(methoxymethyl)-morpholino)quinoline-4-carboxamide (Example 93 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3R)-3-(methoxymethyl)-2-methylmorpholino)-quinoline-4 -carboxamide (Example 97); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methylmorpholino)-quinoline-4-carboxamide (Example 102); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-ethylmorpholino)quinoline-4-carboxamide (Example 106); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 107); and a pharmaceutically acceptable salt thereof.

[0137] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2Heterocyclyl rings include halogen, cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, tri Optionally substituted with one or more substituents independently selected from the group consisting of fluoromethoxy, trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, isopropyl, cyclopropyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy. .

[0138] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-thiomorpholinoquinoline-4 -carboxamide (Example 3), or a pharmaceutically acceptable salt thereof.

[0139] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, isopropyl, cyclopropyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy. .

[0140] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2- Dimethyl-3-oxomorpholino)quinoline-4-carboxamide (Example 16), or a pharmaceutically acceptable salt thereof.

[0141] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, isopropyl, cyclopropyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy. . In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy.

[0142] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6,6- Dimethyl-2-oxo-1,3-oxazinan-3-yl)quinoline-4-carboxamide (Example 112), or a pharmaceutically acceptable salt thereof.

[0143] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3-alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, isopropyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy.

[0144] In some embodiments, the compound or pharmaceutically acceptable salt is 6-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-N-(2-((R)- 4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4-carboxamide (Example 77), or a pharmaceutically acceptable salt thereof.

[0145] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy.

[0146] In some embodiments, the compounds and pharmaceutically acceptable salts are 6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2- oxoethyl)quinoline-4-carboxamide (Example 75); 6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2- oxoethyl)quinoline-4-carboxamide (Example 76); and a pharmaceutically acceptable salt thereof.

[0147] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy.

[0148] In some embodiments, the compound or pharmaceutically acceptable salt is 6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(2-((R)- 4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4-carboxamide (Example 98), or a pharmaceutically acceptable salt thereof.

[0149] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, isopropyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy.

[0150] In some embodiments, the compound or pharmaceutically acceptable salt is 6-(1R,5S)-9-oxa-3-azabicyclo[3.3.1]nonan-3-yl)-N-(2- ((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4-carboxamide (Example 194), or a pharmaceutically acceptable salt thereof.

[0151] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy.

[0152] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,2- oxazinan-2-yl)quinoline-4-carboxamide (Example 1), or a pharmaceutically acceptable salt thereof.

[0153] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3-alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy.

[0154] In some embodiments, the compounds and pharmaceutically acceptable salts are N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-7-methyl-1,4-oxazepan-4-yl)quinoline-4- Carboxamide (Example 61); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-7-methyl-1,4-oxazepan-4-yl)quinoline-4- Carboxamide (Example 62); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methyl-1,4-oxazepan-4-yl)quinoline-4- Carboxamide (Example 63); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-methyl-1,4-oxazepan-4-yl)quinoline-4- Carboxamide (Example 64); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,4-oxazepan-4-yl)quinoline-4-carboxamide (Example 91); and a pharmaceutically acceptable salt thereof.

[0155] In some embodiments, R 2 The heterocyclyl ring is: [ka] and Heterocyclyl rings include halogen, cyano, oxo, C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~6 -Alkyl, C 3~6 -cycloalkyl, C 1~6 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In one aspect, R 2 Heterocyclyl rings include halogen, cyano, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -alkyl, optionally substituted with one or more substituents independently selected from the group consisting of C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -Alkyl, C 1~3 -alkylcarbonyl-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 -Alkyl may be further substituted with one or more halogens. In another aspect, R 2 Heterocyclyl rings include cyano, fluoro, methyl, ethyl, propyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy , trifluoroethoxy, methoxymethyl, trifluoromethoxymethyl, and methylsulfonylmethyl. In another aspect, R 2 The heterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoropropyl, methoxy, and trifluoromethoxy.

[0156] In some embodiments, the compound or pharmaceutically acceptable salt is 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-N-(2-((R)- 4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4-carboxamide (Example 79), or a pharmaceutically acceptable salt thereof.

[0157] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,2-oxazinan-2-yl)quinoline-4-carboxamide (Example 1); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-3-fluoro-6-morpholinoquinoline-4-carboxamide (Example 2); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-thiomorpholinoquinoline-4-carboxamide (Example 3); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-difluoromorpholino)quinoline-4-carboxamide (Example 4); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2,6,6-tetrafluoromorpholino)-quinoline-4-carboxamide (Example 5 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl )quinoline-4-carboxamide (Example 6); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-8-methyl-6-morpholinoquinoline-4-carboxamide (Example 9); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-7-methyl-6-morpholinoquinoline-4-carboxamide (Example 10); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,5-dimethyl-2-oxooxazolidin-3-yl)quinoline-4-carboxamide (implemented) Example 13); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethyl-3-oxomorpholino)-quinoline-4-carboxamide (Example 16) ; N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-7-methyl-1,4-oxazepan-4-yl)-quinoline-4 -carboxamide (Example 61); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-7-methyl-1,4-oxazepan-4-yl)-quinoline-4 -carboxamide (Example 62); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methyl-1,4-oxazepan-4-yl)-quinoline-4 -carboxamide (Example 63); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-methyl-1,4-oxazepan-4-yl)-quinoline-4 -carboxamide (Example 64); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 67); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6S)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 68); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-(fluoromethyl)-morpholino)quinoline-4-carboxamide (Example 69 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6R)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 70); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(fluoromethyl)-morpholino)quinoline-4-carboxamide (Example 71 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-methylmorpholino)-quinoline-4-carboxamide (Example 72); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-(trifluoromethyl)-morpholino)quinoline-4-carboxamide (Example 73); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(trifluoromethyl)-morpholino)quinoline-4-carboxamide (Example 74); 6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2- oxoethyl)quinoline-4-carboxamide (Example 75); 6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2- oxoethyl)quinoline-4-carboxamide (Example 76); 6-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4- Carboxamide (Example 77); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,6S)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 78); 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4- Carboxamide (Example 79); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-methylmorpholino)-quinoline-4-carboxamide (Example 80); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3S)-2,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 81); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3S)-2,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 82); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3R)-2,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 83); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-(trifluoromethyl)-morpholino)quinoline-4-carboxamide isomer 1 (Example 84); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R*)-3-(trifluoromethyl)-morpholino)quinoline-4-carboxamide isomer 2 (Example 85); 6-(3-oxa-9-azabicyclo[3.3.1]nonan-9-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4- Carboxamide (Example 86); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,5R)-2,5-dimethylmorpholino)-quinoline-4-carboxamide (Example 87); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethylmorpholino)-quinoline-4-carboxamide (Example 88); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-(methoxymethyl)-morpholino)quinoline-4-carboxamide (Example 89 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,5R)-3,5-dimethyl-morpholino)quinoline-4-carboxamide (Example 90); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,4-oxazepan-4-yl)quinoline-4-carboxamide (Example 91); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-((methylsulfonyl)-methyl)morpholino)quinoline-4-carboxamide( Example 92); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(methoxymethyl)-morpholino)quinoline-4-carboxamide (Example 93 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-((methylsulfonyl)-methyl)morpholino)quinoline-4-carboxamide( Example 94); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-(2-methoxyethyl)-morpholino)quinoline-4-carboxamide (implemented) Example 95); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3S)-3-(methoxymethyl)-2-methylmorpholino)quinoline-4- Carboxamide (Example 96); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3R)-3-(methoxymethyl)-2-methylmorpholino)quinoline-4- Carboxamide (Example 97); 6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4- Carboxamide (Example 98); 7-Bromo-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,5R)-3,5-dimethyl-morpholino)quinoline-4- Carboxamide (Example 100); (R)-5-chloro-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 101); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methylmorpholino)-quinoline-4-carboxamide (Example 102); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3S,5S)-3,5-dimethylmorpholino)-quinoline-4-carboxamide (Example 103); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((3R,5R)-3,5-dimethylmorpholino)-quinoline-4-carboxamide (Example 105); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-ethylmorpholino)quinoline-4-carboxamide (Example 106); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 107); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-3-methylmorpholino)-quinoline-4-carboxamide (Example 108); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-2-methyl-6-morpholinoquinoline-4-carboxamide (Example 109); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6,6-dimethyl-2-oxo-1,3-oxazinan-3-yl)quinoline- 4-carboxamide (Example 112); (R)-7-chloro-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 179); (R)-8-chloro-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 180); 6-((1R,5S)-9-oxa-3-azabicyclo[3.3.1]nonan-3-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2- oxoethyl)quinoline-4-carboxamide (Example 194); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,4-dimethyloxazol-5-yl)quinoline-4-carboxamide (Example 215); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,5-dimethylisoxazol-4-yl)-quinoline-4-carboxamide (Example 216 ); and a pharmaceutically acceptable salt thereof.

[0158] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,2-oxazinan-2-yl)quinoline-4-carboxamide (Example 1); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-3-fluoro-6-morpholinoquinoline-4-carboxamide (Example 2); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-difluoromorpholino)quinoline-4-carboxamide (Example 4); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-8-methyl-6-morpholinoquinoline-4-carboxamide (Example 9); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 67); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6S)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 68); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-(fluoromethyl)morpholino)-quinoline-4-carboxamide (Example 69 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6R)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 70); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(fluoromethyl)morpholino)-quinoline-4-carboxamide (Example 71 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-methylmorpholino)-quinoline-4-carboxamide (Example 72); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-(trifluoromethyl)-morpholino)quinoline-4-carboxamide (Example 73); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(trifluoromethyl)-morpholino)quinoline-4-carboxamide (Example 74); 6-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2- oxoethyl)quinoline-4-carboxamide (Example 75); 6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2- oxoethyl)quinoline-4-carboxamide (Example 76); 6-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4- Carboxamide (Example 77); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,6S)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 78); 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4- Carboxamide (Example 79); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-methylmorpholino)-quinoline-4-carboxamide (Example 80); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3S)-2,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 81); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2S,3S)-2,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 82); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2,2-dimethylmorpholino)-quinoline-4-carboxamide (Example 88); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-(methoxymethyl)-morpholino)quinoline-4-carboxamide (Example 89 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(methoxymethyl)-morpholino)quinoline-4-carboxamide (Example 93 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,3R)-3-(methoxymethyl)-2-methylmorpholino)quinoline-4- Carboxamide (Example 97); 6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4- Carboxamide (Example 98); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-methylmorpholino)-quinoline-4-carboxamide (Example 102); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-3-ethylmorpholino)quinoline-4-carboxamide (Example 106); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethylmorpholino)-quinoline-4-carboxamide (Example 107); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-2-methyl-6-morpholinoquinoline-4-carboxamide (Example 109); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6,6-dimethyl-2-oxo-1,3-oxazinan-3-yl)quinoline- 4-carboxamide (Example 112); and a pharmaceutically acceptable salt thereof.

[0159] C.R. 2 is spiroheterocyclyl In some embodiments, the present disclosure provides formulas (I), (II), (III-A), (III-B), (III-C), (III-D), (III-E), A compound having the structure (IV) or (IV-A), or a pharmaceutically acceptable salt thereof (wherein R 2 is a spiroheterocyclyl containing a total of 6 to 11 ring atoms; a spiroheterocyclyl (i) contains two saturated rings; and (ii) has (a) 1 or 2 nitrogen ring atoms. (b) has 1 or 2 nitrogen ring atoms and 1 or 2 oxygen ring atoms, and the remaining ring atoms are carbon; or (c) has one nitrogen ring atom and one sulfur ring atom, the remaining ring atoms are carbon, and (iii) halogen, oxo, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl). In one aspect, R 2 Spiroheterocyclyl has (a) 1 or 2 nitrogen ring atoms and the remaining ring atoms are carbon, or (b) 1 or 2 nitrogen ring atoms and 1 or 2 oxygen ring atoms. and the remaining ring atoms are carbon. In another aspect, R 2 Spiroheterocyclyl has 1 or 2 nitrogen ring atoms and optionally 1 or 2 oxygen ring atoms, the remaining ring atoms being carbon. In another aspect, R 2 Spiroheterocyclyl has one nitrogen ring atom and the remaining ring atoms are carbon. In another aspect, R 2 Spiroheterocyclyl has two nitrogen ring atoms and the remaining ring atoms are carbon. In another aspect, R 2 Spiroheterocyclyl has one nitrogen ring atom and one oxygen ring atom, and the remaining ring atoms are carbon. In another aspect, R 2 Spiroheterocyclyl has one nitrogen ring atom and two oxygen ring atoms, and the remaining ring atoms are carbon.

[0160] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] selected from the group consisting of One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl.

[0161] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] selected from the group consisting of One or both rings may be halogen, C1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl.

[0162] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] selected from the group consisting of One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl.

[0163] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] selected from the group consisting of; One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl.

[0164] In some embodiments, R 2 The spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl.

[0165] In some embodiments, R 2 The spiroheterocyclyl ring is optionally substituted with one or more halogens. In one aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more fluoro.

[0166] In some embodiments, R 2 A spiroheterocyclyl ring has one or more C 1~3 -Optionally substituted with alkyl.

[0167] In some embodiments, R 2 A spiroheterocyclyl ring has one or more C 1~3 -Optionally substituted with haloalkyl.

[0168] In some embodiments, R 2 A spiroheterocyclyl ring has one or more C 1~3 -Optionally substituted with alkoxy.

[0169] In some embodiments, R 2 A spiroheterocyclyl ring has one or more C 1~3 -Optionally substituted with haloalkoxy.

[0170] In some embodiments, R 2 A spiroheterocyclyl ring has one or more C 1~3 -Optionally substituted with alkylcarbonyl. In one aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more methylcarbonyls.

[0171] In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy , methoxycarbonyl, ethylcarbonyl, and isopropylcarbonyl.

[0172] In some embodiments, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0173] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 The spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, and trifluoroethoxy. optionally substituted with one or more substituents independently selected from the group consisting of: In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0174] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-azaspiro[3.3]heptan-2-yl)-quinoline-4-carboxamide (Example 17 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-fluoro-2-azaspiro[3.3]heptan-2-yl)quinoline-4-carboxamide ( Example 155); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-(trifluoromethyl)-2-azaspiro[3.3]heptan-2-yl)quinoline- 4-carboxamide (Example 150); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-methyl-2-azaspiro[3.3]heptan-2-yl)quinoline-4-carboxamide ( Example 149); and a pharmaceutically acceptable salt thereof.

[0175] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 The spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, and Optionally substituted with one or more substituents independently selected from the group consisting of methylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and methylcarbonyl.

[0176] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-6-(6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)-N-(2-( 4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4-carboxamide (Example 184), or a pharmaceutically acceptable salt thereof.

[0177] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 Spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0178] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-thia- 6-Azaspiro[3.3]heptan-6-yl)quinoline-4-carboxamide (Example 222), or a pharmaceutically acceptable salt thereof.

[0179] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 Spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0180] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethyl-1-oxa-6-azaspiro[3.3]heptan-6-yl) Quinoline-4-carboxamide (Example 18); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-oxa-6-azaspiro[3.3]heptan-6-yl)quinoline-4-carboxamide ( Example 153); and a pharmaceutically acceptable salt thereof.

[0181] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 Spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0182] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxa- 6-Azaspiro[3.3]heptan-6-yl)quinoline-4-carboxamide (Example 166), or a pharmaceutically acceptable salt thereof.

[0183] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 Spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0184] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-azaspiro[3.4]octan-2-yl)quinoline-4-carboxamide (Example 139) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,5-difluoro-2-azaspiro[3.4]octan-2-yl)quinoline-4- Carboxamide (Example 141); and a pharmaceutically acceptable salt thereof.

[0185] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 The spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0186] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,8- Dioxa-2-azaspiro[3.4]octan-2-yl)quinoline-4-carboxamide (Example 163), or a pharmaceutically acceptable salt thereof.

[0187] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 The spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, and trifluoroethoxy. optionally substituted with one or more substituents independently selected from the group consisting of: In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0188] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 The spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0189] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(8-oxa- 5-Azaspiro[3.5]nonan-5-yl)quinoline-4-carboxamide (Example 104), or a pharmaceutically acceptable salt thereof.

[0190] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 The spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0191] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-oxa- 9-Azaspiro[5.5]undecane-9-yl)quinoline-4-carboxamide (Example 162), or a pharmaceutically acceptable salt thereof.

[0192] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 Spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0193] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,9- Dioxa-4-azaspiro[5.5]undecane-4-yl)quinoline-4-carboxamide (Example 99), or a pharmaceutically acceptable salt thereof.

[0194] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 Spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, and trifluoroethoxy. optionally substituted with one or more substituents independently selected from the group consisting of: In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0195] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(7-oxo- 6-oxa-8-azaspiro[4.5]decane-8-yl)quinoline-4-carboxamide (Example 111), or a pharmaceutically acceptable salt thereof.

[0196] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 Spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, and trifluoroethoxy. optionally substituted with one or more substituents independently selected from the group consisting of: In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0197] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxo- 1-oxa-3-azaspiro[5.5]undecan-3-yl)quinoline-4-carboxamide (Example 110), or a pharmaceutically acceptable salt thereof.

[0198] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 Spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0199] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxa- 7-Azaspiro[3.5]nonan-7-yl)quinoline-4-carboxamide (Example 229), or a pharmaceutically acceptable salt thereof.

[0200] In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 Spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0201] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,4- Dioxa-8-azaspiro[4.5]decane-8-yl)quinoline-4-carboxamide (Example 228), or a pharmaceutically acceptable salt thereof. In some embodiments, R 2 The two saturated rings of spiroheterocyclyl are: [ka] and One or both rings may be halogen, C 1~6 -Alkyl, C 1~6 -Haloalkyl, C 1~6 -alkoxy, C 1~6 -haloalkoxy, and C 1~6 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In one aspect, R 2 The spiroheterocyclyl ring contains halogen, C 1~3 -Alkyl, C 1~3 -Haloalkyl, C 1~3 -alkoxy, C 1~3 -haloalkoxy, and C 1~3 -alkylcarbonyl, optionally substituted with one or more substituents independently selected from the group consisting of -alkylcarbonyl. In another aspect, R 2 Spiroheterocyclyl rings include fluoro, methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, methyl Optionally substituted with one or more substituents independently selected from the group consisting of carbonyl, and ethylcarbonyl. In another aspect, R 2 The spiroheterocyclyl ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, methyl, ethyl, fluoromethyl, difluoromethyl, and trifluoromethyl.

[0202] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,5- Dioxa-9-azaspiro[5.5]undecane-9-yl)quinoline-4-carboxamide (Example 227), or a pharmaceutically acceptable salt thereof.

[0203] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-azaspiro[3.3]heptan-2-yl)quinoline-4-carboxamide (Example 17) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethyl-1-oxa-6-azaspiro[3.3]heptan-6-yl) Quinoline-4-carboxamide (Example 18); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-azaspiro[3.3]heptan-1-yl)quinoline-4-carboxamide (Example 19) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5-azaspiro[2.5]octan-5-yl)quinoline-4-carboxamide (Example 46) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5-azaspiro[2.4]heptan-5-yl)quinoline-4-carboxamide (Example 49) ; N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-6-(fluoromethyl)-5-azaspiro[2.4]heptan-5-yl )quinoline-4-carboxamide (Example 58); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,9-dioxa-4-azaspiro[5.5]undecane-4-yl)quinoline-4- Carboxamide (Example 99); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(8-oxa-5-azaspiro[3.5]nonan-5-yl)quinoline-4-carboxamide ( Example 104); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxo-1-oxa-3-azaspiro[5.5]undecane-3-yl)quinoline- 4-carboxamide (Example 110); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(7-oxo-6-oxa-8-azaspiro[4.5]decane-8-yl)quinoline- 4-carboxamide (Example 111); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-azaspiro[3.4]octan-2-yl)quinoline-4-carboxamide (Example 139) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,5-difluoro-2-azaspiro[3.4]octan-2-yl)quinoline-4- Carboxamide (Example 141); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-methyl-2-azaspiro[3.3]heptan-2-yl)quinoline-4-carboxamide ( Example 149); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-(trifluoromethyl)-2-azaspiro[3.3]heptan-2-yl)quinoline- 4-carboxamide (Example 150); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-oxa-6-azaspiro[3.3]heptan-6-yl)quinoline-4-carboxamide ( Example 153); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-fluoro-2-azaspiro[3.3]heptan-2-yl)quinoline-4-carboxamide ( Example 155); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-oxa-9-azaspiro[5.5]undecane-9-yl)quinoline-4-carboxamide( Example 162); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,8-dioxa-2-azaspiro[3.4]octan-2-yl)quinoline-4- Carboxamide (Example 163); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5-azaspiro[2.3]hexan-5-yl)quinoline-4-carboxamide (Example 164) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoline-4-carboxamide ( Example 166); (R)-6-(6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)quinoline-4- Carboxamide (Example 184); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-thia-6-azaspiro[3.3]heptan-6-yl)quinoline-4-carboxamide ( Example 222); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,5-dioxa-9-azaspiro[5.5]undecane-9-yl)quinoline-4- Carboxamide (Example 227); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,4-dioxa-8-azaspiro[4.5]decane-8-yl)quinoline-4- Carboxamide (Example 228); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxa-7-azaspiro[3.5]nonan-7-yl)quinoline-4-carboxamide ( Example 229); and a pharmaceutically acceptable salt thereof.

[0204] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3,3-dimethyl-1-oxa-6-azaspiro[3.3]heptan-6-yl) Quinoline-4-carboxamide (Example 18); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1,9-dioxa-4-azaspiro[5.5]undecane-4-yl)quinoline-4- Carboxamide (Example 99); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxo-1-oxa-3-azaspiro[5.5]undecane-3-yl)quinoline- 4-carboxamide (Example 110); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-(trifluoromethyl)-2-azaspiro[3.3]heptan-2-yl)quinoline- 4-carboxamide (Example 150); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-oxa-6-azaspiro[3.3]heptan-6-yl)quinoline-4-carboxamide ( Example 153); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(5,8-dioxa-2-azaspiro[3.4]octan-2-yl)quinoline-4- Carboxamide (Example 163); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)quinoline-4-carboxamide ( Example 166); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(1-thia-6-azaspiro[3.3]heptan-6-yl)quinoline-4-carboxamide ( Example 222); and a pharmaceutically acceptable salt thereof.

[0205] D.R. 2 is azetidinyl In some embodiments, the present disclosure provides compounds having the structure of formula (V): [ka] and a pharmaceutically acceptable salt thereof (wherein, R 1 ,R 3 ,R 4 ,R 5 , and R 6 are independently selected from the group consisting of hydrogen, chloro, fluoro, and methyl; R 20a and R 20b are independently hydrogen and C 1~3 - selected from the group consisting of alkyl; R 20c and R 20d are independently hydrogen, fluoro, hydroxy, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~3 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -alkyl, phenyl, tolyl, phenyl-C 1~3 -alkyl, morpholinyl, C 1~3 -alkylsulfonyl-C 1~3 -alkyl, and C 1~3 -alkyl-carbonylamino-C 1~3 -alkyl, and C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 3~6 -cycloalkyl-C 1~3 -Alkyl, C 1~3 -alkoxy, C 3~6 -cycloalkoxy, C 1~3 -alkoxy-C 1~3 -alkyl, phenyl, and phenyl-C 1~3 -alkyl may be further substituted with one or more halogens, and R 20e and R 20f are independently hydrogen and C 1~3 -alkyl).

[0206] In some embodiments of compounds having the structure of formula (V), R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is selected from the group consisting of chloro, fluoro, and methyl, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In one aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is chloro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is fluoro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is methyl and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen.

[0207] In some embodiments of compounds having the structure of formula (V), R 1 ,R 3 ,R 4 ,R 5 , and R 6 are all hydrogen.

[0208] In some embodiments of the compound having the structure of formula (V), R 20a and R 20b are independently selected from the group consisting of hydrogen and methyl; R 20c and R 20d are independently hydrogen, fluoro, hydroxy, C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, C 1~3 -alkoxy-C 1~3 -alkyl, morpholinyl, C 1~3 -alkylsulfonyl-C 1~3 -alkyl, and C 1~3 -alkyl-carbonylamino-C 1~3 - selected from the group consisting of alkyl;C 1~3 -Alkyl, C 3~6 -cycloalkyl, C 1~3 -alkoxy, and C 1~3 -alkoxy-C 1~3 -alkyl may be further substituted with one or more halogens; and R 20e and R 20f are independently selected from the group consisting of hydrogen and methyl.

[0209] In some embodiments of compounds having the structure of formula (V), R 20c and R 20d are independently hydrogen, fluoro, C 1~3 -Alkyl, C 1~3 -alkoxy, morpholinyl, and C 1~3 -alkyl-carbonylamino-C 1~3 - selected from the group consisting of alkyl;C 1~3 -Alkyl and C 1~3 -Alkoxy may be further substituted with one or more halogens.

[0210] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)-3-methylazetidin-1-yl)quinoline-4-carboxamide (Example 27); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-(fluoromethyl)azetidin-1-yl)quinoline-4-carboxamide (Example 113) ; (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(3-methoxy-3-methylazetidin-1-yl)quinoline-4-carboxamide (Example 151); and a pharmaceutically acceptable salt thereof.

[0211] E.R. 2 is morpholinyl In some embodiments, the present disclosure provides a compound having the structure of formula (VI): [ka] and a pharmaceutically acceptable salt thereof (wherein, R 1 ,R 3 ,R 4 ,R 5 , and R 6 are independently selected from the group consisting of hydrogen, chloro, fluoro, and methyl; R 30a and R 30b are independently hydrogen, C 1~3-alkyl, halo-C 1~3 -alkyl, and C 1~3 -alkoxy-C 1~3 - selected from the group consisting of alkyl; R 30c and R 30d are independently hydrogen, halogen, C 1~3 -alkyl, halo-C 1~3 -Alkyl, C 1~3 -alkoxy-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 - selected from the group consisting of alkyl; R 30e and R 30f are independently hydrogen, halogen, C 1~3 -alkyl, halo-C 1~3 -Alkyl, C 1~3 -alkoxy-C 1~3 -alkyl, and C 1~3 -alkylsulfonyl-C 1~3 - selected from the group consisting of alkyl; and R 30g and R 30h are independently hydrogen, C 1~3 -alkyl, halo-C 1~3 alkyl, and C 1~3 -alkoxy-C 1~3 -alkyl).

[0212] In some embodiments of compounds having the structure of formula (VI), R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is selected from the group consisting of chloro, fluoro, and methyl, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In one aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is chloro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is fluoro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is methyl and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen.

[0213] In some embodiments of compounds having the structure of formula (VI), R 1 ,R 3 ,R 4 ,R 5 , and R 6 are all hydrogen.

[0214] In some embodiments of the compound having the structure of formula (VI), R 30a and R 30b are independently hydrogen, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 -alkoxy-C 1~2 - selected from the group consisting of alkyl; R 30c and R 30d are independently hydrogen, halogen, C 1~2 -alkyl, halo-C 1~2 -Alkyl, C 1~2 -alkoxy-C 1~2 -alkyl, and C 1~2 -alkylsulfonyl-C 1~2 - selected from the group consisting of alkyl; R 30e and R 30f are independently hydrogen, halogen, C 1~2 -alkyl, halo-C 1~2 -Alkyl, C 1~2 -alkoxy-C 1~2 -alkyl, and C 1~2 -alkylsulfonyl-C 1~2 - selected from the group consisting of alkyl; and R 30g and R 30h are independently hydrogen, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 -alkoxy-C 1~2 - selected from the group consisting of alkyl.

[0215] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-8-methyl-6-morpholinoquinoline-4-carboxamide (Example 9); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide (Example 67); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6S)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 68); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-(fluoromethyl)morpholino)-quinoline-4-carboxamide (Example 69 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((2R,6R)-2,6-dimethylmorpholino)-quinoline-4-carboxamide (Example 70); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-(fluoromethyl)morpholino)-quinoline-4-carboxamide (Example 71 ); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((R)-2-methylmorpholino)-quinoline-4-carboxamide (Example 72); N-(2-((R)-4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-((S)-2-methylmorpholino)-quinoline-4-carboxamide (Example 80); and a pharmaceutically acceptable salt thereof.

[0216] F.R. 2 is piperidin-1-yl In some embodiments, the present disclosure provides a compound having the structure of formula (VII): [ka] and a pharmaceutically acceptable salt thereof (wherein, R 1 ,R 3 ,R 4 ,R 5 , and R 6 are independently selected from the group consisting of hydrogen, chloro, fluoro, and methyl; R 40a and R 40b are independently hydrogen, C 1~3 -alkyl, and halo-C 1~3 - selected from the group consisting of alkyl; R 40c and R 40d are independently hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 -alkyl, and C 1~3 - selected from the group consisting of alkoxy; R 40e and R 40f are independently hydrogen, fluoro, hydroxy, oxo, C 1~3 -alkyl, halo-C 1~3 -alkyl, cyclopropyl, and C 1~3 - selected from the group consisting of alkoxy; R 40g and R 40h are independently hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 alkyl, and C 1~3 -alkoxy; and R 40i and R 40j are independently hydrogen, C 1~3 -alkyl, and halo-C 1~3 -alkyl).

[0217] In some embodiments of compounds having the structure of formula (VII), R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is selected from the group consisting of chloro, fluoro, and methyl, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6All substituents are hydrogen. In one aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is chloro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is fluoro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is methyl and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen.

[0218] In some embodiments of compounds having the structure of formula (VII), R 1 ,R 3 ,R 4 ,R 5 , and R 6 are all hydrogen.

[0219] In some embodiments of the compound having the structure of formula (VII), R 40a and R 40b are independently hydrogen, C 1~3 -alkyl, and halo-C 1~3 - selected from the group consisting of alkyl; R 40c and R 40d are independently hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 -alkyl, and C 1~3 - selected from the group consisting of alkoxy; R 40e and R 40f are independently hydrogen, fluoro, hydroxy, C 1~3 -alkyl, halo-C 1~3 -alkyl, cyclopropyl, and C 1~3 - selected from the group consisting of alkoxy; R 40g and R 40h are independently hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 alkyl, and C 1~3 -alkoxy; and R 40i and R 40j are independently hydrogen, C 1~3 -alkyl, and halo-C 1~3 - selected from the group consisting of alkyl.

[0220] In some embodiments of the compound having the structure of formula (VII), R 40a and R 40b are independently hydrogen, C 1~2 -alkyl, and halo-C 1~2 - selected from the group consisting of alkyl; R 40c and R 40d are independently hydrogen, fluoro, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 - selected from the group consisting of alkoxy; R 40e and R 40f are independently hydrogen, fluoro, hydroxy, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 - selected from the group consisting of alkoxy; R 40g and R 40h are independently hydrogen, fluoro, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 -alkoxy; and R 40i and R 40j are independently hydrogen, C 1~2 -alkyl, and halo-C 1~2 - selected from the group consisting of alkyl.

[0221] In some embodiments, the compounds and pharmaceutically acceptable salts are (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-methoxypiperidin-1-yl)quinoline-4-carboxamide (Example 8); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-methoxy-4-methylpiperidin-1-yl)quinoline-4-carboxamide (Example 42 ); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-fluoropiperidin-1-yl)quinoline-4-carboxamide (Example 205); (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(4-oxopiperidin-1-yl)quinoline-4-carboxamide (Example 230); and a pharmaceutically acceptable salt thereof.

[0222] G.R. 2 is piperidin-4-yl In some embodiments, the present disclosure provides compounds having the structure of formula (VIII): [ka] and a pharmaceutically acceptable salt thereof (wherein, R 1 ,R 3 ,R 4 ,R 5 , and R 6 are independently selected from the group consisting of hydrogen, chloro, fluoro, and methyl; R 50a and R 50b are independently hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 -alkyl, and C 1~3 - selected from the group consisting of alkoxy; R 50c and R 50d are independently hydrogen, C 1~3 -alkyl, and halo-C 1~3 -alkyl or both are oxo; R 50e is hydrogen, C 1~3 -alkyl, halo-C 1~3 -Alkyl, C 1~3 -alkoxy-C 2~3 -Alkyl, C 1~3 -alkyl-carbonyl, and C 3~6 -cycloalkyl-carbonyl; R 50f and R 50g are independently hydrogen, C 1~3 -alkyl, and halo-C 1~3 -alkyl or both are oxo; R 50h and R 50i are independently hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 -alkyl, and C 1~3 -alkoxy; and R 50j is selected from the group consisting of hydrogen and fluoro).

[0223] In some embodiments of compounds having the structure of formula (VIII), R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is selected from the group consisting of chloro, fluoro, and methyl, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In one aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is chloro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is fluoro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is methyl and the remaining R 1 ,R3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen.

[0224] In some embodiments of compounds having the structure of formula (VIII), R 1 ,R 3 ,R 4 ,R 5 , and R 6 are all hydrogen.

[0225] In some embodiments of the compound having the structure of formula (VIII), R 1 ,R 3 ,R 4 ,R 5 , and R 6 is selected from the group consisting of hydrogen, fluoro, and methyl; R 50a and R 50b are independently hydrogen, fluoro, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 - selected from the group consisting of alkoxy; R 50c and R 50d are independently hydrogen, C 1~2 -alkyl, and halo-C 1~2 - selected from the group consisting of alkyl; R 50e is hydrogen, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 -alkoxy-C 2~3 - selected from the group consisting of alkyl; R 50f and R 50g are independently hydrogen, C 1~2 -alkyl, and halo-C 1~2 - selected from the group consisting of alkyl; R 50h and R 50i are independently hydrogen, fluoro, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 -alkoxy; and R 50j is selected from the group consisting of hydrogen and fluoro.

[0226] In some embodiments of compounds having the structure of formula (VIII), R 50a ,R 50b ,R 50h ,R 50i , and R 50j At least one of them is fluoro.

[0227] H.R. 2 is 3-oxomorpholinyl In some embodiments, the present disclosure provides a compound having the structure of formula (IX): [ka] and a pharmaceutically acceptable salt thereof (wherein, R 1 ,R 3 ,R 4 ,R 5 , and R 6 are independently selected from the group consisting of hydrogen, chloro, fluoro, and methyl; R 60a and R 60b are independently hydrogen and C 1~3 - selected from the group consisting of alkyl; R 60c and R 60d are independently hydrogen and C 1~3 - selected from the group consisting of alkyl; and R 60e and R 60f are independently hydrogen and C 1~3 -alkyl).

[0228] In some embodiments of compounds having the structure of formula (IX), R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is selected from the group consisting of chloro, fluoro, and methyl, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In one aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is chloro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is fluoro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is methyl and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen.

[0229] In some embodiments of compounds having the structure of formula (IX), R 1 ,R 3 ,R 4 ,R 5 , and R 6 are all hydrogen.

[0230] In some embodiments of the compound having the structure of formula (IX), R 4 is methyl; and R 1 ,R 3 ,R 5 , and R 6 are all hydrogen.

[0231] In some embodiments of the compound having the structure of formula (IX), R 1 ,R 3 ,R 4 ,R 5 , and R 6 is selected from the group consisting of hydrogen, fluoro, and methyl; R 60a and R 60b are independently hydrogen and C 1~2 - selected from the group consisting of alkyl; R 60c and R 60d are independently hydrogen and C 1~2 - selected from the group consisting of alkyl; and R 60e and R 60f are independently hydrogen and C 1~2 - selected from the group consisting of alkyl.

[0232] I.R. 2 is 5,8-dioxa-2-azaspiro[3.4]octan-2-yl In some embodiments, the present disclosure provides a compound having the structure of formula (X): [ka] and a pharmaceutically acceptable salt thereof (wherein, R 1 ,R 3 ,R 4 ,R 5 , and R 6 are independently selected from the group consisting of hydrogen, chloro, fluoro, and methyl; R 70a and R 70b are independently hydrogen and C 1~3 - selected from the group consisting of alkyl; R 70c and R 70d are independently hydrogen and C 1~3 - selected from the group consisting of alkyl; R 70e and R 70f are independently hydrogen and C 1~3 - selected from the group consisting of alkyl; and R 70g and R 70h are independently hydrogen and C 1~3 -alkyl).

[0233] In some embodiments of compounds having the structure of formula (X), R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is selected from the group consisting of chloro, fluoro, and methyl, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In one aspect, R 1 ,R 3 ,R 4 ,R 5 , and R6 One of the substituents is chloro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is fluoro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is methyl and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen.

[0234] In some embodiments of compounds having the structure of formula (X), R 1 ,R 3 ,R 4 ,R 5 , and R 6 are all hydrogen.

[0235] In some embodiments of the compound having the structure of formula (X), R 1 ,R 3 ,R 4 ,R 5 , and R 6 is selected from the group consisting of hydrogen, fluoro, and methyl; R 70a and R 70b are independently hydrogen and C 1~2 - selected from the group consisting of alkyl; R 70c and R 70d are independently hydrogen and C 1~2 - selected from the group consisting of alkyl; R 70e and R 70f are independently hydrogen and C 1~2 - selected from the group consisting of alkyl; and R 70g and R 70h are independently hydrogen and C 1~2 - selected from the group consisting of alkyl.

[0236] J.R. 2 is pyridin-3-yl In some embodiments, the present disclosure provides a compound having the structure of formula (XI): [ka] and a pharmaceutically acceptable salt thereof (wherein, R 1 ,R 3 ,R 4 ,R 5 , and R 6 are independently selected from the group consisting of hydrogen, chloro, fluoro, and methyl; R 80a is hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 -alkyl, and C 1~3 - selected from the group consisting of alkoxy; R 80b is hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 -alkyl, and C 1~3 - selected from the group consisting of alkoxy; R 80c is hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 -alkyl, and C 1~3 -alkoxy; and R 80d is hydrogen, fluoro, C 1~3 -alkyl, halo-C 1~3 -alkyl, and C 1~3 -alkoxy).

[0237] In some embodiments of compounds having the structure of formula (XI), R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is selected from the group consisting of chloro, fluoro, and methyl, and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In one aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is chloro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is fluoro and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen. In another aspect, R 1 ,R 3 ,R 4 ,R 5 , and R 6 One of the substituents is methyl and the remaining R 1 ,R 3 ,R 4 ,R 5 , and R 6 All substituents are hydrogen.

[0238] In some embodiments of compounds having the structure of formula (XI), R 1 ,R 3 ,R 4 ,R 5 , and R 6 are all hydrogen.

[0239] In some embodiments of the compound having the structure of formula (XI), R 1 ,R 3 ,R 4 ,R 5 , and R 6 is selected from the group consisting of hydrogen, fluoro, and methyl; R 80a is hydrogen, fluoro, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 - selected from the group consisting of alkoxy; R 80b is hydrogen, fluoro, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 - selected from the group consisting of alkoxy; R 80c is hydrogen, fluoro, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 -alkoxy; and R 80d is hydrogen, fluoro, C 1~2 -alkyl, halo-C 1~2 -alkyl, and C 1~2 - selected from the group consisting of alkoxy.

[0240] In some embodiments, the compound or pharmaceutically acceptable salt is (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-(6-(difluoro methyl)pyridin-3-yl)quinoline-4-carboxamide (Example 169), or a pharmaceutically acceptable salt thereof.

[0241] K. Additional Embodiments Any embodiment of the compounds described in this disclosure may be combined with any other suitable embodiments described herein to provide additional embodiments. For example, one embodiment provides R 1 ,R 3 ,R 4 ,R 5 , and / or R 6 Possible groups for R are listed individually or together, and another embodiment is 2 When describing possible groups for R, these embodiments can be combined to 1 ,R 3 ,R 4 ,R 5 , and / or R 6 Possible groups described for R 2 It is understood that additional embodiments may be provided that are described in conjunction with the possible groups described for. In other words, for any of the compound embodiments described in this disclosure, R 2 The substituent is the following R 2 may be as defined in any of the embodiments.

[0242] Compounds of the present disclosure have pharmaceutically acceptable FAP inhibitory activity measured as described for the hFAP inhibition assay (tight binder) reported in the Examples below. In one embodiment, the compound has an IC of less than about 100 nM 50It has FAP inhibitory activity at certain concentrations. In another embodiment, the compound has an IC of less than about 50 nM 50 It has FAP inhibitory activity at certain concentrations. In another embodiment, the compound has an IC of less than about 10 nM 50 It has FAP inhibitory activity at certain concentrations. In another embodiment, the compound has an IC of less than about 1 nM 50 It has FAP inhibitory activity at certain concentrations.

[0243] In some embodiments, compounds of the present disclosure have a pharmaceutically acceptable surface plasmon resonance (SPR) pK measured as described for the SPR assay reported in the Examples below. d has value. In one embodiment, the compound has a surface plasmon resonance (SPR) pK of greater than about 7 d has value. In another embodiment, the compound has a surface plasmon resonance (SPR) pK of greater than about 8 d has value. In another embodiment, the compound has an SPR pK of greater than about 9 d has value. In another embodiment, the compound has an SPR pK of greater than about 10 d has value.

[0244] In some embodiments, the compounds of the present disclosure have a pharmaceutically effective anti-FAP relative to PREP measured as described for the hFAP inhibition assay (tight binder) and hPREP inhibition assay reported in the Examples below. with acceptable selectivity. In one embodiment, the compound has at least about 50 times higher selectivity for FAP versus PREP. In another embodiment, the compound has at least about 100-fold higher selectivity for FAP versus PREP. In another embodiment, the compound has at least about 1,000 times higher selectivity for FAP versus PREP. In another embodiment, the compound has at least about 10,000 times higher selectivity for FAP versus PREP. In another embodiment, the compound has a PREP IC of greater than about 0.1 μM 50 has value. In another embodiment, the compound has a PREP IC of greater than about 1.0 μM 50 has value. In another embodiment, the compound has a PREP IC of greater than about 10.0 μM 50 has value.

[0245] In some embodiments, compounds of the present disclosure have a pharmacological activity with respect to FAP against DPP7 measured as described for the hFAP inhibition assay (tight binder) and DPP7 selectivity assay reported in the Examples below. with acceptable selectivity. In one embodiment, the compound has at least about 50 times higher selectivity for FAP versus DPP7. In another embodiment, the compound has at least about 100-fold higher selectivity for FAP versus DPP7. In another embodiment, the compound has at least about 1,000 times higher selectivity for FAP versus DPP7. In another embodiment, the compound has at least about 10,000 times higher selectivity for FAP versus DPP7. In another embodiment, the compound has an IC for DPP7 of greater than about 0.1 μM 50 has value. In another embodiment, the compound has an IC for DPP7 of greater than about 1 μM. 50 has value. In another embodiment, the compound has an IC for DPP7 of greater than about 10 μM. 50 has value.

[0246] In some embodiments, compounds of the present disclosure are measured as described for the hFAP inhibition assay (tight binder), DPP8 selectivity assay, and DPP9 selectivity assay reported in the Examples below. Has a pharmaceutically acceptable selectivity for FAP over DPP8 and / or DPP9. In one aspect, the compound has selectivity for FAP over DPP8. In another embodiment, the compound has selectivity for FAP over DPP9. In another embodiment, the compound has selectivity for FAP over both DPP8 and DPP9. In one embodiment, the compound has at least about 50 times higher selectivity for FAP versus DPP8 and / or DPP9. In another embodiment, the compound has at least about 100 times higher selectivity for FAP versus DPP8 and / or DPP9. In another embodiment, the compound has at least about 500 times higher selectivity for FAP versus DPP8 and / or DPP9. In another embodiment, the compound has at least about 1,000 times higher selectivity for FAP versus DPP8 and / or DPP9. In another embodiment, the compound has an IC for DPP8 and / or DPP9 of greater than about 0.01 μM. 50 has value. In another embodiment, the compound has an IC for DPP8 and / or DPP9 of greater than about 0.1 μM. 50 has value. In another embodiment, the compound has an IC for DPP8 and / or DPP9 of greater than about 0.4 μM. 50 has value.

[0247] In some embodiments, compounds of the present disclosure have pharmaceutically acceptable metabolic stability as measured as described for the human liver microsome (HLM) assay reported in the Examples below. In one embodiment, the compound has an HLM CL of less than about 300 μL / min / mg int has value. In another embodiment, the compound has an HLM CL of less than about 100 μL / min / mg int has value. In another embodiment, the compound has an HLM CL of less than about 50 μL / min / mg int has value.

[0248] In some embodiments, compounds of the present disclosure have pharmaceutically acceptable metabolic stability as measured as described for the rat hepatocyte (rHep) assay reported in the Examples below. In one embodiment, the compound is about 300 μL / min / 10 6 Subcellular rHep CL int has value. In another embodiment, the compound is about 100 μL / min / 10 6 Subcellular rHep CL int has value. In another embodiment, the compound is about 50 μL / min / 10 6 Subcellular rHep CL int has value.

[0249] In some embodiments, compounds of the present disclosure have a pharmaceutically acceptable Caco-2 AB specific permeability measured as described for the Caco-2 AB specific permeability assay reported in the Examples below. have sex. In one embodiment, the compound is at least about 0.1 x 10 6 It has an apparent Caco-2 specific permeability of cm / s. In another embodiment, the compound is at least about 0.5 x 10 6 It has an apparent Caco-2 specific permeability of cm / s. In another embodiment, the compound is at least about 1 x 10 6 It has an apparent Caco-2 specific permeability of cm / s.

[0250] In some embodiments, compounds of the present disclosure are measured as described for the Caco-2 bidirectional (ABBA)A-B apparent permeability assay reported in the Examples below. It has a pharmaceutically acceptable Caco-2 bidirectional (ABBA) AB apparent permeability. In one embodiment, the compound is at least about 0.1 x 10 6 Caco-2 has a bidirectional (ABBA) AB apparent permeability of cm / s. In another embodiment, the compound is at least about 0.25 x 10 6 Caco-2 has a bidirectional (ABBA) AB apparent permeability of cm / s. In another embodiment, the compound is at least about 0.5 x 10 6 Caco-2 has a bidirectional (ABBA) AB apparent permeability of cm / s.

[0251] In some embodiments, compounds of the present disclosure have pharmaceutically acceptable kinetic solubility measured as described for the kinetic solubility assay reported in the Examples below. In one embodiment, the compound has a kinetic solubility of at least about 1 μM. In another embodiment, the compound has a kinetic solubility of at least about 10 μM. In another embodiment, the compound has a kinetic solubility of at least about 25 μM. In another embodiment, the compound has a kinetic solubility of at least about 50 μM.

[0252] L.Salt The compounds of the present disclosure may exist in salt or non-salt form (ie, as the free base), and the present disclosure encompasses both salt and non-salt forms. The compounds may form acid or base addition salts. Generally, acid addition salts can be prepared using a variety of inorganic or organic acids. Such salts can typically be formed using a variety of methods known in the art, for example, by mixing the compound and an acid (e.g., a stoichiometric amount of the acid). . This mixing can occur in water, an organic solvent (eg, ether, ethyl acetate, ethanol, methanol, isopropanol, or acetonitrile), or an aqueous / organic mixture. In another embodiment, the acid addition salt is, for example, trifluoroacetate, formate, acetate or hydrochloric acid. Generally, base addition salts include various inorganic or organic bases, such as alkali or alkaline earth metal salts, such as sodium, calcium or magnesium salts, or other metal salts, such as potassium or zinc, or ammonium salts. They can be prepared using salts or salts with organic bases such as methylamine, dimethylamine, trimethylamine, piperidine or morpholine. Those skilled in the art will be aware of the general principles and techniques for preparing pharmaceutical salts, such as those described in J.Pharm.Sci.1977 66,1. Examples of pharmaceutically acceptable salts are also described in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

[0253] M.isomer The compounds and salts of the present disclosure may have one or more geometric, optical, enantiomeric, and may exist in diastereoisomeric forms. Unless otherwise specified, references to a particular compound include all such isomeric forms, including racemic mixtures and other mixtures. Where appropriate, such isomers may be separated from their mixtures by the application or adaptation of known methods, such as chromatographic and recrystallization techniques. Where appropriate, such isomers may be prepared by application or adaptation of known methods. In some embodiments, a single stereoisomer is obtained by isolating it from a mixture of isomers (eg, a racemate) using, for example, chiral chromatographic separation. In other embodiments, single stereoisomers are obtained, for example, by direct synthesis from chiral starting materials.

[0254] Certain enantiomers of the compounds described herein may be more active than other enantiomers of the same compound. In one embodiment, the compound, or a pharmaceutically acceptable salt thereof, is present in an enantiomeric excess (%ee) of ≧90, ≧95%, ≧96%, ≧97, ≧98% or ≧99%. It is a single enantiomer.

[0255] In one embodiment, the single enantiomer is present in ≧99% enantiomeric excess (%ee). In another embodiment, the present disclosure provides ≧90, ≧95%, ≧96%, ≧97, ≧98% or ≧99% mirror image in combination with one or more pharmaceutically acceptable excipients. The present invention relates to a compound that is a single enantiomer, or a pharmaceutically acceptable salt thereof, present in %ee, or a pharmaceutical composition comprising a pharmaceutically acceptable salt thereof. In one embodiment, the single enantiomer is present in ≧99% enantiomeric excess (%ee).

[0256] N. Additional forms The compounds and salts of the present disclosure may exist in various tautomeric forms, and the present specification encompasses all such tautomeric forms. "Tautomers" are structural isomers that exist in equilibrium resulting from the migration of hydrogen atoms. The compounds of the present disclosure, and their pharmaceutically acceptable salts, may exist in solvated (such as hydrated) and unsolvated forms; includes.

[0257] The compounds of the present disclosure, and their pharmaceutically acceptable salts, may exist in crystalline or amorphous forms, and the present specification encompasses all such forms.

[0258] The compounds and salts of this disclosure can be isotopically labeled (or "radiolabeled"). In that example, one or more atoms are replaced by an atom having an atomic mass or mass number that differs from that typically found in nature. The present specification encompasses isotopically labeled forms of the compounds disclosed herein. Examples of isotopes that may be incorporated include: 2 H (also written as "D" in reference to Deuterium), 3 H (also written as “T” for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O and 36 Examples include Cl. The isotope used will depend on the particular use of the radiolabeled derivative. For example, for in vitro receptor labeling and competition assays, 3 H or 14 C is often useful. For radioactive imaging applications, 11 C is often useful. In some embodiments, the radionuclide is 3 It is H. In some embodiments, the radionuclide is 14 It is C. In some embodiments, the radionuclide is 11 It is C.

[0259] O. Intermediate In some embodiments, the present disclosure provides additional compounds that are useful as intermediates for preparing compounds of the present disclosure, and pharmaceutically acceptable salts thereof.

[0260] III.How to use The disclosed compounds of the present disclosure, and pharmaceutically acceptable salts thereof, are inhibitors of prolyl endopeptidase fibroblast activation protein (FAP) activity. FAP is an endopeptidase that enzymatically cleaves substances involved in glucose and lipid metabolism, fibrinolysis, and collagen production.

[0261] FAP is thought to cleave and inactivate human fibroblast growth factor 21 (FGF-21) (Biochem J 2016,473,605), a protein involved in the regulation of glucose and lipid metabolism. Inhibition of FAP increases endogenous FGF-21 levels and signaling, resulting in, for example, decreased adiposity, improved insulin sensitivity, improved glucose tolerance, reduced body weight, and / or reduced cardiovascular disease mortality. It is assumed that

[0262] FAP is also thought to cleave human α2-antiplasmin (α2AP), a protein involved in the regulation of fibrosis and fibrinolysis (Blood 2004 103,3783). Tissue repair includes coagulation that causes fibrin deposition. Fibrin in blood clots is normally lysed primarily by plasmin as it is converted from its inactive form (plasminogen) by plasminogen activators. Fibrinolysis is inhibited by plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (PAI-2), and α2AP (Experimental & Molecular Medicine 2020,52,367 ), all of which are induced by tissue trauma. FAP converts α2AP to a more active form that reduces plasmin activity and increases fibrin deposition at the injury site. Inhibition of FAP is hypothesized to increase fibrinolysis and improve tissue regeneration at the site of injury (J Thromb Haemost 2013,11,2029;Proteomics Clin.Appl.2014,8,454).

[0263] FAP further promotes collagen production and deposition and is thought to play a role in increasing fibrosis via altered extracellular matrix (ECM) turnover (J Biol Chem 2016,8,291). Inhibition of FAP is hypothesized to result in decreased collagen deposition and reduced inflammation (Inflamm Bowel Dis. 2018, 18, 332).

[0264] In view of the above, inhibition of FAP collectively reduces fibrosis and inflammation by reducing hepatic stellate cell activity and increasing fibrinolysis, and further via increasing FGF21 signaling and improving glucose tolerance. It is hypothesized that this will lead to positive metabolic effects.

[0265] Accordingly, in some embodiments, the present disclosure provides a method for treating a FAP-mediated condition in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. Provided are methods for treating or preventing.

[0266] In some embodiments, the present disclosure is characterized by overexpression of FAP in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. Methods for treating or preventing disease conditions are provided.

[0267] In some embodiments, the present disclosure provides methods for treating or preventing liver disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. provide a method for doing so. In one aspect, the liver disease is fatty liver disease. In another embodiment, the liver disease is non-alcoholic fatty liver disease (NAFLD). In another embodiment, NAFLD is selected from the group consisting of isolated steatosis, nonalcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis. In another aspect, the liver disease is end stage liver disease. In another embodiment, the subject also suffers from or is susceptible to one or more conditions selected from the group consisting of obesity, dyslipidemia, insulin resistance, type 2 diabetes, and renal failure.

[0268] In some embodiments, the present disclosure provides a method for treating liver disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. The target is 27kg / m 2 ~40kg / m 2 have a body mass index (BMI) of In one aspect, the subject is 30 kg / m 2 ~39.9kg / m 2 have a BMI of In another aspect, the subject is at least 40 kg / m 2 have a BMI of In another aspect, the subject is overweight. In another aspect, the subject is obese. In another embodiment, the liver disease is NAFLD. In another embodiment, the liver disease is NASH. In another aspect, the liver disease is liver fibrosis. In another embodiment, the liver disease is cirrhosis.

[0269] In some embodiments, the present disclosure provides a method for treating liver disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. and the subject also suffers from or is susceptible to dyslipidemia. In another embodiment, the liver disease is NAFLD. In another embodiment, the liver disease is NASH. In another aspect, the liver disease is liver fibrosis. In another embodiment, the liver disease is cirrhosis.

[0270] In some embodiments, the present disclosure provides a method for treating liver disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. and the subject also suffers from or is susceptible to insulin resistance. In another embodiment, the liver disease is NAFLD. In another embodiment, the liver disease is NASH. In another aspect, the liver disease is liver fibrosis. In another embodiment, the liver disease is cirrhosis.

[0271] In some embodiments, the present disclosure provides a method for treating liver disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. and the subject also suffers from or is susceptible to at least one of type 2 diabetes and renal failure. In another embodiment, the liver disease is NAFLD. In another embodiment, the liver disease is NASH. In another aspect, the liver disease is liver fibrosis. In another embodiment, the liver disease is cirrhosis.

[0272] In some embodiments, the present disclosure provides a method for treating liver disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. and the subject also suffers from or is susceptible to type 2 diabetes. In another embodiment, the liver disease is NAFLD. In another embodiment, the liver disease is NASH. In another aspect, the liver disease is liver fibrosis. In another embodiment, the liver disease is cirrhosis.

[0273] In some embodiments, the present disclosure provides a method for treating liver disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. and the subject also suffers from or is susceptible to renal failure. In another embodiment, the liver disease is NAFLD. In another embodiment, the liver disease is NASH. In another aspect, the liver disease is liver fibrosis. In another embodiment, the liver disease is cirrhosis.

[0274] In some embodiments, the present disclosure provides a method for reducing liver fat in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. I will provide a. In one aspect, the subject suffers from or is susceptible to NAFLD. In another embodiment, the subject has or is susceptible to NASH. In another aspect, the subject suffers from or is susceptible to liver fibrosis. In another aspect, the subject has or is susceptible to liver cirrhosis. In another embodiment, the subject also suffers from or is susceptible to one or more conditions selected from the group consisting of obesity, dyslipidemia, insulin resistance, type 2 diabetes, and renal failure.

[0275] In some embodiments, the present disclosure provides treatment for non-alcoholic fatty liver disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. Provided are methods for treating or preventing NAFLD. In one aspect, the NAFLD is stage 1 NAFLD. In another embodiment, the NAFLD is stage 2 NAFLD. In another embodiment, the NAFLD is stage 3 NAFLD. In another embodiment, the NAFLD is stage 4 NAFLD. For example, see “The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases,” Hepatology, 2018, Vol. 67, No. 1. In another embodiment, the subject also suffers from or is susceptible to one or more conditions selected from the group consisting of obesity, dyslipidemia, insulin resistance, type 2 diabetes, and renal failure.

[0276] In some embodiments, the present disclosure provides treatment for non-alcoholic fatty liver disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. Provided are methods for treating or preventing NASH. In one aspect, the NASH is stage 1 NASH. In another embodiment, the NASH is stage 2 NASH. In another embodiment, the NASH is stage 3 NASH. In another embodiment, the NASH is stage 4 NASH. In another embodiment, the subject also suffers from or is susceptible to one or more conditions selected from the group consisting of obesity, dyslipidemia, insulin resistance, type 2 diabetes, and renal failure.

[0277] In some embodiments, the present disclosure provides methods for treating liver fibrosis in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. Provide methods for prevention. In one aspect, the subject is suffering from stage 3 liver fibrosis. In another embodiment, the subject also suffers from or is susceptible to one or more conditions selected from the group consisting of obesity, dyslipidemia, insulin resistance, type 2 diabetes, and renal failure.

[0278] In some embodiments, the present disclosure provides for treating or preventing liver cirrhosis in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. provide a method for In one aspect, the subject has stage F4 cirrhosis. In another embodiment, the subject also suffers from or is susceptible to one or more conditions selected from the group consisting of obesity, dyslipidemia, insulin resistance, type 2 diabetes, and renal failure.

[0279] In some embodiments, the present disclosure provides methods for treating type 2 diabetes in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. Provide methods for prevention. In one aspect, the subject is a subject suffering from diabetic kidney disease. In another aspect, the subject is suffering from renal failure. In another aspect, administration of the compound is an adjunct to diet and exercise. In another embodiment, administration of the compound also reduces body weight and / or treats obesity. In another aspect, the subject is 27 kg / m 2 ~40kg / m 2 have a BMI of In another aspect, the subject is 30 kg / m 2 ~39.9kg / m 2 have a BMI of In another aspect, the subject is at least 40 kg / m 2 have a BMI of In another aspect, the subject is overweight. In another aspect, the subject is obese.

[0280] In some embodiments, the present disclosure provides a method of improving glycemic control in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. do. In one embodiment, the subject is a subject suffering from type 2 diabetes. In another aspect, the subject is a subject suffering from diabetic kidney disease. In another aspect, the subject is suffering from renal failure. In another aspect, administration of the compound is an adjunct to diet and exercise. In another embodiment, administration of the compound also reduces body weight and / or treats obesity. In another aspect, the subject is 27 kg / m 2 ~40kg / m 2 have a BMI of In another aspect, the subject is 30 kg / m 2 ~39.9kg / m 2 have a BMI of In another aspect, the subject is at least 40 kg / m 2have a BMI of In another aspect, the subject is overweight. In another aspect, the subject is obese.

[0281] In some embodiments, the present disclosure provides methods for reducing blood glucose levels in a subject with type 2 diabetes and diabetic kidney disease by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. Provide ways to improve management. In one aspect, administration of the compound is an adjunct to diet and exercise. In another embodiment, administration of the compound also reduces body weight and / or treats obesity. In another aspect, the subject is 27 kg / m 2 ~40kg / m 2 have a BMI of In another aspect, the subject is 30 kg / m 2 ~39.9kg / m 2 have a BMI of In another aspect, the subject is at least 40 kg / m 2 have a BMI of In another aspect, the subject is overweight. In another aspect, the subject is obese.

[0282] In some embodiments, the present disclosure provides glycemic control in a subject with type 2 diabetes and renal failure by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. Provide ways to improve. In one aspect, administration of the compound is an adjunct to diet and exercise. In another embodiment, administration of the compound also reduces body weight and / or treats obesity. In another aspect, the subject is 27 kg / m 2 ~40kg / m 2 have a BMI of In another aspect, the subject is 30 kg / m 2 ~39.9kg / m 2 have a BMI of In another aspect, the subject is at least 40 kg / m 2 have a BMI of In another aspect, the subject is overweight. In another aspect, the subject is obese.

[0283] In some embodiments, the present disclosure provides for treating or preventing insulin resistance in a subject by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. provide a method. In another embodiment, the subject is a subject suffering from type 2 diabetes. In another aspect, the subject is a subject suffering from diabetic kidney disease. In another aspect, the subject is suffering from renal failure. Insulin resistance can be measured using, for example, the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) and / or the MATSUDA index. HOMA-IR is described, for example, in Diabetologia 1985, 28, 412, which is incorporated herein by reference in its entirety. The MATSUDA index is described, for example, in Diabetes Care 1999, 22, 1462, which is incorporated herein by reference in its entirety.

[0284] In some embodiments, the present disclosure provides methods for treating glucose intolerance in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. Provide a way to prevent it. In one embodiment, the subject is a subject suffering from type 2 diabetes. In another aspect, the subject is a subject suffering from diabetic kidney disease. In another aspect, the subject is suffering from renal failure.

[0285] In some embodiments, the present disclosure provides for treating a cardiovascular condition in a subject in need of treatment by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. provide a method. In one aspect, the cardiovascular condition is selected from the group consisting of heart failure, cardiomyopathy, atherosclerosis, venous thromboembolism, and atrial fibrillation. In one aspect, the cardiovascular condition is heart failure. In another embodiment, the cardiovascular condition is heart failure with preserved ejection fraction (HFpEF). In another aspect, the cardiovascular condition is cardiomyopathy. In another aspect, the cardiomyopathy is from hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy, ischemic cardiomyopathy, ischemic cardiomyopathy, dilated cardiomyopathy, and idiopathic cardiomyopathy. selected from the group. In another aspect, the cardiovascular condition is atherosclerosis. In another aspect, the cardiovascular condition is venous thromboembolism. In another aspect, the cardiovascular condition is atrial fibrillation.

[0286] In some embodiments, the present disclosure provides for treating obesity or obesity-related conditions in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. provide a method. In one aspect, the obesity-related condition is an obesity-related metabolic condition. In another embodiment, the obesity-related condition is selected from the group consisting of insulin resistance, prediabetes, type 2 diabetes, glucose intolerance, elevated fasting blood glucose, and glucagonoma. In another aspect, the obesity-related condition is dyslipidemia. In another aspect, the obesity-related condition is a cardiovascular condition selected from the group consisting of heart failure, cardiomyopathy, atherosclerosis, venous thromboembolism, and atrial fibrillation. In another aspect, the obesity-related condition is renal disease.

[0287] In some embodiments, the present disclosure provides a method of reducing body weight in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. . In one embodiment, the subject is a subject suffering from type 2 diabetes. In another aspect, the subject is a subject suffering from diabetic kidney disease. In another aspect, the subject is suffering from renal failure. In another aspect, administration of the compound is an adjunct to diet and exercise. In another embodiment, administration of the compound also reduces body weight and / or treats obesity. In another aspect, the subject is 27 kg / m 2 ~40kg / m 2 have a BMI of In another aspect, the subject is 30 kg / m 2 ~39.9kg / m 2 have a BMI of In another aspect, the subject is at least 40 kg / m 2 have a BMI of In another aspect, the subject is overweight. In another aspect, the subject is obese. In another embodiment, the subject's weight is reduced by, for example, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40%.

[0288] In some embodiments, the present disclosure provides a method of reducing body fat in a subject in need of treatment by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. I will provide a. In another embodiment, the subject is a subject suffering from type 2 diabetes. In another aspect, the subject is a subject suffering from diabetic kidney disease. In another aspect, the subject is suffering from renal failure. In another aspect, administration of the compound is an adjunct to diet and exercise. In another embodiment, administration of the compound also reduces body weight and / or treats obesity. In another aspect, the subject is 27 kg / m 2 ~40kg / m 2 have a BMI of In another aspect, the subject is 30 kg / m 2 ~39.9kg / m 2 have a BMI of In another aspect, the subject is at least 40 kg / m 2 have a BMI of In another aspect, the subject is overweight. In another aspect, the subject is obese. In another embodiment, the fat is liver fat.

[0289] In some embodiments, the present disclosure provides methods for treating or preventing fibrosis in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. provide a method for doing so. In one aspect, the fibrosis is interstitial lung disease. In another aspect, the fibrosis is interstitial lung disease with progressive fibrosis. In another aspect, the interstitial lung disease is pulmonary fibrosis. In another embodiment, the interstitial lung disease is idiopathic pulmonary fibrosis (IPF).

[0290] In some embodiments, the present disclosure provides a method for promoting tissue repair in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. I will provide a. In one aspect, the subject has worsened cardiac tissue damage due to myocardial infarction.

[0291] In some embodiments, the present disclosure provides methods for promoting wound healing and / or in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. A method of reducing adhesion is provided. In one aspect, administration of the compound promotes wound healing and / or reduces adhesion through increased fibrinolysis.

[0292] In some embodiments, the present disclosure provides methods for treating or preventing keloid disorders in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. provide a method for doing so. In one aspect, the keloid disorder is selected from the group consisting of scar formation, keloid tumor, and keloid scar.

[0293] In some embodiments, the present disclosure provides for treating or preventing inflammation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. provide a method for In one aspect, the inflammation is chronic inflammation. In one aspect, the chronic inflammation is selected from the group consisting of rheumatoid arthritis, osteoarthritis, and Crohn's disease. In another aspect, the chronic inflammation is rheumatoid arthritis.

[0294] In some embodiments, the present disclosure provides a method of treating cancer in a subject in need of treatment by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. provide. In one aspect, the cancer is breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular cancer, esophageal cancer, hypopharyngeal cancer, nasopharyngeal cancer, laryngeal cancer, myeloma cell, bladder cancer, cholangiocellular carcinoma, renal clear cell carcinoma, neuroendocrine tumor, tumor-induced osteomalacia, sarcoma, CUP (carcinoma of unknown primary origin), thymic carcinoma, tendonoma, glioma, astrocytoma , cervical cancer, and prostate cancer. In another aspect, the cancer is hepatocellular carcinoma.

[0295] The subject treated will usually be a human or non-human mammal, particularly a human. Suitable subjects are also domestic or wild animals; companion animals (including dogs, cats, etc.); livestock (including horses, cows and other ruminants, pigs, poultry, rabbits, etc.); primates (rhesus macaques, including monkeys such as macaques (also known as cynomolgus monkeys or long-tailed macaques), marmosets, tamarins, chimpanzees, macaques; and rodents (including rats, mice, gerbils, guinea pigs, etc.).

[0296] In some embodiments, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

[0297] In some embodiments, the present disclosure provides the use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, to treat or prevent a FAP-mediated condition as discussed above. do.

[0298] In some embodiments, the present disclosure provides a compound of Formula I, or a pharmaceutically acceptable compound thereof, for the manufacture of a medicament for treating or preventing a FAP-mediated condition as discussed above. Provides the use of salt.

[0299] IV. Combination therapy and fixed dose combinations The compounds of the present disclosure can be used in the methods described above as a single pharmacological agent or in combination with other pharmacological agents or procedures. Such combination therapy may be achieved by simultaneous, sequential or separate administration of the individual components of the treatment. These combination therapies (and corresponding combination products) utilize compounds of the present disclosure within the dosage ranges described in this application and other pharmacological agents typically within their approved dosage ranges. do.

[0300] In some embodiments, the present disclosure provides combinations suitable for use in the treatment of conditions selected from the previously discussed conditions, wherein the combination comprises a compound of the present disclosure, or a pharmaceutically acceptable compound thereof. salts, and sodium-glucose transporter 2 (SGLT2) inhibitors. In one aspect, the SGLT2 inhibitor is selected from the group consisting of canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, and remogliflozin. In another embodiment, the SGLT2 inhibitor is dapagliflozin.

[0301] In some embodiments, the present disclosure provides combinations suitable for use in the treatment of conditions selected from the previously discussed conditions, wherein the combination comprises a compound of the present disclosure, or a pharmaceutically acceptable compound thereof. salt, and metformin.

[0302] In some embodiments, the present disclosure provides combinations suitable for use in the treatment of conditions selected from the previously discussed conditions, wherein the combination comprises a compound of the present disclosure, or a pharmaceutically acceptable compound thereof. salts, and glucagon-like peptide-1 receptor (GLP1) agonists. In one aspect, the SGLT2 inhibitor is selected from the group consisting of exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, and semaglutide.

[0303] In some embodiments, the present disclosure provides combinations suitable for use in the treatment of conditions selected from the previously discussed conditions, wherein the combination comprises a compound of the present disclosure, or a pharmaceutically acceptable compound thereof. salts, and dipeptidyl peptidase 4 (DPP4) inhibitors. In one aspect, the DPP4 inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, anagliptin, teneligliptin, alogliptin, trelagliptin, omarigliptin, evogliptin, gosogliptin, and dutogliptin.

[0304] In some embodiments, the present disclosure provides combinations suitable for use in the treatment of conditions selected from the previously discussed conditions, wherein the combination comprises a compound of the present disclosure, or a pharmaceutically acceptable compound thereof. salts, and peroxisome proliferator-activated receptor (PPAR) agonists. In one aspect, the PPAR agonist is a PPARα agonist. In another embodiment, the PPAR agonist is a PPARγ agonist. In another embodiment, the PPAR agonist is a PPARα / γ agonist. In another embodiment, the PPAR agonist is selected from the group consisting of clofibrate, gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate. In another embodiment, the PPAR agonist is a thiazolidinedione. In another aspect, the thiazolidinedione is selected from the group consisting of pioglitazone, rosiglitazone, lobeglitazone, and riboglitazone. In another embodiment, the PPAR agonist stimulates hepatic expression of FGF21.

[0305] In some embodiments, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof; one or more selected from SGLT2 inhibitors, metformin, GLP1 agonists, DPP4 inhibitors, and PPAR agonists. A pharmaceutical composition is provided that includes a pharmacological agent; and a pharmaceutically acceptable diluent or carrier. Such a combination may be used for the manufacture of a medicament for use in the treatment of conditions selected from those previously discussed. In one aspect, the pharmaceutical composition includes an SGLT2 inhibitor. In another aspect, the pharmaceutical composition comprises metformin. In another embodiment, the pharmaceutical composition includes a GLP1 agonist. In another embodiment, the pharmaceutical composition includes a DPP4 inhibitor. In another embodiment, the pharmaceutical composition includes a PPAR agonist.

[0306] In some embodiments, the present disclosure provides a combination suitable for use in the treatment of cancer, the combination comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor. . In one aspect, the immune checkpoint inhibitor is selected from the group consisting of anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA4 antibodies, TLR7 agonists, CD40 agonists, Lag-3 antagonists, and OX40 agonists. In another embodiment, the immune checkpoint inhibitor is an anti-PD-1 antibody (eg, pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo), etc.). In another embodiment, the immune checkpoint inhibitor is an anti-PD-L1 antibody (eg, atezolizumab (Tecentriq), atezolizumab (Bavencio), durvalumab (Imfinzi), etc.). In another embodiment, the immune checkpoint inhibitor is an anti-CTLA4 antibody (eg, ipilimumab (Yervoy), tremelimumab, etc.). In another aspect, the cancer is selected from the group consisting of pancreatic cancer, colon cancer, and rectal cancer.

[0307] V. Pharmaceutical composition Compounds of the present disclosure, and pharmaceutically acceptable salts thereof, can be administered as a pharmaceutical composition containing one or more pharmaceutically acceptable excipients. Thus, in some embodiments, the present disclosure provides pharmaceutical compositions comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. .

[0308] The excipient selected for inclusion in a particular composition will depend on factors such as the mode of administration and the form of the composition provided. Suitable pharmaceutically acceptable excipients are well known to those skilled in the art and can be found, for example, in the Handbook of Pharmaceutical Excipients, edited by Rowe, Ray C; Sheskey, Paul J; Quinn, Marian, Sixth Edition, Pharmaceutical Press. It is described in. Pharmaceutically acceptable excipients can be used, for example, as adjuvants, diluents, carriers, stabilizers, flavorants, colorants, fillers, binders, disintegrants, lubricants, lubricants, thickeners and coatings. It can work. As one of ordinary skill in the art will recognize, a particular pharmaceutically acceptable excipient will depend on the amount of excipient present in the composition and what other excipients are present in the composition. , may serve more than one function, and may serve alternative functions.

[0309] The compositions are suitable for oral use (e.g. as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (e.g. as creams, ointments, gels). or as an aqueous or oily solution or suspension), by inhalation (e.g., as a finely divided powder or liquid aerosol), by insufflation (e.g., as a finely divided powder), or parenterally (e.g., intravenously, subcutaneously or intramuscularly). It may be in a form suitable for internal administration (as a sterile aqueous or oily solution) or as a suppository for rectal administration. The compositions may be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and / or preservative agents.

[0310] The total daily dose will necessarily vary depending on the subject being treated, the particular route of administration, any concurrent therapy, and the severity of the disease being treated; Multiple doses may be included. The particular dosage will depend on, for example, the condition being treated; the age, weight, general health, sex, and diet of the subject; the route of administration; the interval between doses; the rate of excretion; and other drugs being co-administered to the subject. can be adjusted accordingly. A physician of ordinary skill in the art, provided with the disclosure of this application, will be able to determine the appropriate dosage and regimen for the administration of a therapeutic agent to a subject and the duration of treatment according to methods well known in the therapeutic drug art. Such dosages and regimens may be adjusted as necessary over time. The compound of the present disclosure, or a pharmaceutically acceptable salt thereof, typically has a dosage of 2.5 to 5000 mg / m 2 (body area of ​​the animal), or a unit dose within the range of approximately 0.05-100 mg / kg, which usually provides a therapeutically effective dose. Unit dosage forms such as tablets or capsules may contain, for example, 0.1 to 500 mg, 0.1 to 250 mg, 0.1 to 100 mg of active ingredient.

[0311] In some embodiments, the present disclosure provides a medicament for use in therapy comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. A composition is provided.

[0312] In some embodiments, the present disclosure provides a method for treating FAP-mediated pathologies comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions for use in therapy are provided. In one aspect, the FAP-mediated condition is selected from the group consisting of liver disease, type 2 diabetes, cardiovascular conditions, obesity, obesity-related conditions, fibrosis, keloid disorders, inflammation, and cancer.

[0313] VI.Kit The present disclosure further provides unit dosage forms and unit dosage forms comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, contained within packaging material for treating one or more of the previously discussed disease conditions. The kit includes a label or package insert indicating that the kit can be used for.

[0314] In some embodiments, the kit provides a unit dosage form and a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, contained within packaging material for treating a FAP-mediated condition. Contains a label or package insert indicating that it can be used for In another embodiment, the FAP-mediated condition is liver disease. In another aspect, the liver disease is selected from the group consisting of fatty liver disease, end-stage liver disease, and cirrhosis. In another embodiment, the liver disease is selected from the group consisting of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).

[0315] In some embodiments, the kit comprises: (a) a first unit dosage form comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof; (b) an SGLT2 inhibitor, metformin, a GLP1 agonist, a DPP4 inhibitor; (c) a container means for containing said first dosage form and a second dosage form; and ( d) comprising a label or package insert indicating that the first unit dosage form and the second unit dosage form can be used to treat a FAP-mediated condition.

[0316] VII. Preparation method The disclosure further provides formulas (I), (II), (III-A), (III-B), (III-C), (III-D), (III-E), (IV), (IV - Process for the preparation of compounds of A), (V), (VI), (VII), (VIII), (IX), (X), and (XI) and their pharmaceutically acceptable salts I will provide a.

[0317] Schemes 1 to 14 below illustrate compounds of formula (II) (wherein R 1 ,R 2 ,R 3 ,R 4 ,R 5 ,R 6 and X 1 is as defined in formula (I), and R 7 is an alkyl group (e.g. methyl, ethyl, or tert-butyl) and 2 ,X 3 and X 4 indicates a synthetic route to a leaving group (eg, Cl, Br, I, or OTf). Those skilled in the art will appreciate that these methods are representative and do not encompass all possible methods for preparing the compounds of this disclosure. R in each scheme X Substituents, unless otherwise specified, are as defined for the compounds of this disclosure. The processes for the preparation described in Schemes 1-14 include formulas (2), (4), (6), (8), (9), (10), (11), (12), (13 ) or (14) can be carried out starting from any enantiomer or racemic mixture of the compound of formula (II) or any stereoisomer of formula (II). Ru.

[0318] Scheme 1 [ka] Scheme 1 shows a synthetic route to certain compounds of formula (II). A compound of formula (2) may be reacted with a compound of formula (3) to obtain a compound of formula (II). The reaction is carried out in the presence of a base (typically an organic base such as DIPEA or TEA) using a solvent such as DCM, DME, EtOAc or MeCN, or mixtures thereof, and typically from 0°C to 60°C. can be carried out using a suitable coupling reagent (eg, HATU, HOBt / EDC, or T3P) at a temperature in the range of .

[0319] Scheme 2 [ka] Scheme 2 depicts additional synthetic routes to certain compounds of formula (II). A compound of formula (4) may be reacted with a compound of formula (5) to obtain a compound of formula (II). The reaction is carried out in the presence of a base (typically an organic base such as DIPEA or TEA) using a solvent such as DCM, DME, EtOAc or MeCN, or mixtures thereof, and typically from 0°C to 60°C. can be carried out using a suitable coupling reagent (eg, HATU, HOBt / EDC, or T3P) at a temperature in the range of .

[0320] Scheme 3 [ka] Scheme 3 depicts additional synthetic routes to certain compounds of formula (II). Compounds of formula (6) can be prepared in a suitable reagent (typically TFAA) in a solvent such as DCM, DMF, EtOAc or MeCN, or mixtures thereof, at a temperature typically in the range of 0°C to 120°C. or T3P) to a compound of formula (II).

[0321] Scheme 4 [ka] Scheme 4 shows a synthetic route to certain compounds of formula (2). A compound of formula (4) may be reacted with (tert-butoxycarbonyl)-glycine (7) to obtain a compound of formula (8). The reaction is carried out in the presence of a base (typically an organic base such as DIPEA or TEA) using a solvent such as DCM, DME, EtOAc or MeCN, or mixtures thereof, and typically from 0°C to 120°C. can be carried out using a suitable coupling reagent (eg HATU, HOBt / EDC or T3P) at a temperature in the range of .

[0322] Compounds of formula (2) are formed by reacting compounds of formula (8) with a suitable acid (e.g. HCl) in a solvent such as 1,4-dioxane, EtOAc, MeOH or water, or mixtures thereof. obtain. Alternatively, the reaction may be carried out using an acid such as neat TFA or TFA in a solvent such as DCM, typically at temperatures ranging from 0°C to 60°C.

[0323] scheme 5 [ka] Scheme 5 shows a synthetic route to certain compounds of formula (4). The compound of formula (10) is obtained by converting the compound of formula (9) into pure NH 3 or as a solution, e.g. in water or MeOH 3 , or ammonia synthetic equivalents (e.g. NH 4 Cl). The reaction is carried out in the presence of a base (typically an organic base such as DIPEA or TEA) using a solvent such as THF, DME, EtOAc or MeCN, or mixtures thereof, and typically from 0°C to 120°C. A suitable coupling reagent (e.g. HATU, HOBt / EDC, T3P or Boc 2 O).

[0324] Compounds of formula (10) can be reacted with a suitable reagent (typically TFAA) in a solvent such as DCM, DMF, EtOAc or MeCN, or mixtures thereof, at a temperature typically in the range of 0°C to 120°C. or T3P) by dehydration to the compound of formula (11).

[0325] Compounds of formula (4) are prepared by reacting compounds of formula (11) with a suitable acid (e.g. HCl or TsOH) in a solvent such as MeCN, 1,4-dioxane, EtOAc, MeOH or water, or mixtures thereof. It can be formed by Alternatively, the reaction may be carried out using an acid such as neat TFA or TFA in a solvent such as DCM, typically at temperatures ranging from 0°C to 60°C.

[0326] scheme 6 [ka] Scheme 6 shows a synthetic route to certain compounds of formula (6). A compound of formula (12) may be reacted with a compound of formula (3) to obtain a compound of formula (6). The reaction may be carried out under conditions described for analogous reactions described in Scheme 1.

[0327] scheme 7 [ka] Scheme 7 shows a synthetic route to certain compounds of formula (12). A compound of formula (12) can be formed from a compound of formula (13) and (7) via a compound of formula (14). The reaction may be carried out under conditions described for analogous reactions described in Scheme 4.

[0328] scheme 8 [ka] Scheme 8 shows a synthetic route to certain compounds of formula (5). A compound of formula (3) may be reacted with a compound of formula (15) to obtain a compound of formula (16). The reaction is carried out in the presence of a base (typically an organic base such as DIPEA or TEA) using a solvent such as DCM, DME, EtOAc or MeCN, or mixtures thereof, and typically from 0°C to 120°C. can be carried out using a suitable coupling reagent (eg HATU, HOBt / EDC or T3P) at a temperature in the range of .

[0329] A compound of formula (5) can be prepared by combining a compound of formula (16) with a base (e.g. NaOH or LiOH) in an organic solvent (e.g. dioxane, THF or MeOH, or mixtures thereof) and optionally in the presence of water. can be formed by reacting. The reaction may be carried out at a temperature interval from 0° C. to reflux. Or R 7 For compounds of formula (16) where =tert-butyl, the reaction may be carried out with a suitable acid (eg HCl) in a solvent such as 1,4-dioxane, EtOAc, MeOH or water, or mixtures thereof. Alternatively, the reaction may be carried out using an acid such as neat TFA or TFA in a solvent such as DCM, typically at temperatures ranging from 0°C to 60°C.

[0330] scheme 9 [ka] Scheme 9 shows a synthetic route to certain compounds of formula (3). Compounds of formula (18) can be prepared by combining compounds of formula (17) with an acid (e.g. HCl or HCl) in a suitable solvent. 2 S.O. 4 ) or by reaction with an alcohol (eg, MeOH or EtOH) using the alcohol as a solvent. Alternatively, the reaction can be carried out in SOCl in a suitable solvent or using an alcohol (e.g. MeOH or EtOH) as a solvent. 2 can be facilitated by reagents such as Alternatively, a compound of formula (18) may be reacted with an alcohol (e.g. MeOH or EtOH) using a solvent such as DCM, DMF, EtOAc or MeCN, or mixtures thereof, typically at temperatures between 0°C and Facilitated by coupling the reagent (eg, EDC or TBTU) in the presence of a base (such as DIPEA, TEA, or DMAP) at a temperature in the range of 120°C.

[0331] Compound of formula (19) (wherein R 2 is as defined in formula (I) and the point of attachment to the quinoline is through the nitrogen atom), the compound of formula (18) can be combined with the amine H-R 2 (20)(wherein, R 2 (as defined in formula (I)). The reaction is carried out with a base (Cs 2 C.O. 3 A suitable Pd-reagent, e.g. Pd 2 (dba) 3 can be catalyzed by

[0332] Compound of formula (19) (wherein R 2 is as defined in formula (I) and the point of attachment to the quinoline is through the nitrogen atom), the compound of formula (18) can be combined with the amine H-R 2 (20)(wherein, R 2 (as defined in formula (I)). The reaction is carried out with a base (K 2 C.O. 3 or Cs 2 C.O. 3 etc.) in the presence of a suitable Cu-reagent (e.g. CuI or Cu 2 can be catalyzed by O).

[0333] Compounds of formula (3) can be prepared with a base (e.g. NaOH or LiOH) in an organic solvent (e.g. 1,4-dioxane, THF or MeOH, or mixtures thereof) and optionally in the presence of water. 19). The reaction may be carried out at a temperature interval from 0° C. to reflux. Or R 7 For compounds of formula (19) where =tert-butyl, the reaction may be carried out with a suitable acid (eg HCl) in a solvent such as 1,4-dioxane, EtOAc, MeOH or water, or mixtures thereof. Alternatively, a compound of formula (19) (wherein R 7 =tert-butyl), the reaction may be carried out using an acid such as TFA neat or in a solvent such as DCM at temperatures typically in the range of 0°C to 60°C.

[0334] Alternatively, a compound of formula (3) (wherein R 2 is as defined in formula (I) and the point of attachment to the quinoline is through the nitrogen atom) is the amine H-R 2 (20)(wherein, R 2 may be formed directly from a compound of formula (17) by reaction with (as defined in formula (I)). The reaction may be carried out under the conditions described for similar reactions above in Scheme 9.

[0335] scheme 10 [ka] Scheme 10 shows a synthetic route to certain compounds of formula (3). Compound of formula (19) (wherein R 2 is as defined in formula (I) and the point of attachment to the quinoline is through a carbon atom), converts the compound of formula (18) into compound B-R 2 (21) (wherein B is a boronic acid, boronic ester or trifluoroborate, and R 2 (as defined in formula (I)). The reaction is carried out with a base (Na 2 C.O. 3 or K 2 C.O. 3 etc.) in the presence of a suitable Pd-reagent (e.g. Pd(dppf)Cl 2 ) can be catalyzed by

[0336] Compounds of formula (3) may be formed by reacting compounds of formula (19) under conditions described for analogous reactions described in Scheme 9. Alternatively, a compound of formula (3) (wherein R 2 is as defined in formula (I) and the point of attachment to the quinoline is through the carbon atom) is the compound B-R 2 (21) (wherein B is a boronic acid, boronic ester or trifluoroborate, and R 2 may be formed directly from a compound of formula (17) by reaction with (as defined in formula (I)). The reaction may be carried out under the conditions described for the analogous reaction above in Scheme 10.

[0337] scheme 11 [ka] Scheme 11 shows a synthetic route to certain compounds of formula (19). Compounds of formula (22), where B is a boronic acid, boronic ester or trifluoroborate, can be prepared by combining a compound of formula (18) with a bis-boronic acid species (e.g., B 2 (OH) 4 (subdiboric acid) or B 2 pin 2(4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)). The reaction is carried out in a suitable solvent (such as ethanol or 1,4-dioxane) with a base (Na 2 C.O. 3 or K 2 C.O. 3 etc.) in the presence of a suitable Pd-reagent (e.g. Pd(dppf)Cl 2 ) can be catalyzed by

[0338] Compound of formula (19) (wherein R 2 is as defined in formula (I) and the point of attachment to the quinoline is through a carbon atom), the compound of formula (22) can be combined with an aryl halide or aryl pseudohalide of formula (23) ( In the formula, R 2 is as defined in formula (I), and 3 is R through the carbon atom 2 (combined with). The reaction is carried out with a base (Na 2 C.O. 3 or K 2 C.O. 3 etc.) in the presence of a suitable Pd-reagent (e.g. Pd(dppf)Cl 2 ) can be catalyzed by

[0339] scheme 12 [ka] Scheme 12 shows a synthetic route to certain compounds of formula (17). The compound of formula (26) is prepared in the presence of a base (e.g. NaOH) in water at reflux temperature or an elevated temperature typically in the range of 100°C to 160°C in a sealed container in a microwave reactor or in a sealed tube. may be formed by reacting a compound of formula (24) with a 2-ketocarboxylic acid of formula (25), or a salt thereof (eg, sodium salt). A compound of formula (17) can be prepared neat or in a suitable solvent (e.g. water) at an elevated temperature typically in the range of 150°C to 250°C in a sealed container in a microwave reactor or in a sealed tube. ) can be formed by heating the compound.

[0340] scheme 13 [ka] Scheme 13 shows a synthetic route to certain compounds of formula (19). Compound of formula (28) (wherein R 2 is as defined in formula (I) and the point of attachment to the quinoline is through the nitrogen or carbon atom) as described for analogous reactions described in Schemes 9, 10 and 11. can be formed from compounds of formula (27) using synthetic methodologies carried out under conditions.

[0341] The compound of formula (19) is prepared by combining the compound of formula (28) with carbon monoxide (1 to 10 atm) at a temperature typically in the range of 80 to 120°C and a pressure of typically 10 atm in a sealed container. can be formed by reacting. The reaction is carried out using a suitable Pd-reagent (e.g., , Pd(dppf)Cl 2 ) can be catalyzed by

[0342] scheme 14 [ka] Scheme 14 shows a synthetic route to certain compounds of formula (31). Compound of formula (29) (wherein R 50 is as defined in formula (VIII)) can be prepared by reaction with an electrophile such as a ketone of formula (30) following metal halogen exchange using an organometallic reagent (e.g. BuLi). ) may be formed from the compound. The reaction may be carried out in a solvent such as THF at a temperature typically ranging from -78°C to room temperature.

[0343] Compound of formula (31) (wherein R 50j is fluorine) can be formed by reacting a compound of formula (29) with a fluorinating agent (e.g. DAST) in a solvent such as DCM at temperatures typically in the range of -20°C to reflux. .

[0344] Compounds of formula (31) can be converted to compounds of formula (VIII) using synthetic methodologies similar to those described in Schemes 13, 10 and 1.

[0345] (i) the organic reactions described in this disclosure were carried out in accordance with laboratory standards known to those skilled in the art; (ii) some of the reactions described in this disclosure were optionally carried out according to laboratory standards known to those skilled in the art; (iii) Chiral isomers of the compounds in this disclosure may be prepared using chiral resolving agents described in the literature and known to those skilled in the art, or as described in the literature and known to those skilled in the art. may be resolved at any stage of the synthetic process using chiral chromatography methods known to those skilled in the art or as further described in the Examples; (iv) additional and / or other protecting groups; may optionally be required in some of the above steps; and (v) the deprotection step is therefore optionally performed using methods described in the literature and known to those skilled in the art. It should be understood that other implementations may also be implemented. Protection and deprotection of functional groups is described in "Protective Groups in Organic Synthesis" 3rd Ed, T.W. Greene and P.G.M. Wutz, Wiley-Interscience (1999), which publication is incorporated herein by reference.

Example

[0346] VIII. Examples The following description of experiments, procedures, examples, and intermediates is intended to be illustrative of embodiments of the present disclosure and is not intended to be limiting in any way. Other compounds of the present disclosure can be prepared using the methods illustrated in these examples alone or in combination with techniques commonly known in the art.

[0347] A. General conditions Unless otherwise specified, (i) Operations are performed at room temperature (rt), i.e., within the range of 17-25°C, and N 2 carried out under an atmosphere of inert gas such as; (ii) If the reaction involved the use of a microwave reactor, one of the following microwave reactors was used: Biotage Initiator, Personal Chemistry Emrys Optimizer, Personal Chemistry Smith Creator, or CEM Explorer; (iii) The reaction step was generally followed by thin layer chromatography (TLC) and / or analytical high performance liquid chromatography (HPLC or UPLC) coupled to a mass spectrometer (LCMC). (iv) If necessary, the organic solution is anhydrous MgSO 4 Or Na 2 S.O. 4 or by using an ISOLUTE® phase separator, and work-up procedures were performed using conventional phase separation techniques. (v) Evaporation was carried out in vacuum or by rotary evaporation in Genevac HT-4 / EZ-2 or Biotage V10; (vi) Unless otherwise specified, flash column chromatography is performed using Merck Silica Gel (Art. 9385) or Biotage® SNAP cartridges (40-63 μm silica, 4-330 g), Biotage® Sfar Silica HC D Cartridge (20μm, 10~100g), Interchim puriFlash(TM) Cartridge (25μm, 4~120g), Interchim puriFlash(TM) Cartridge (50μm, 25~330g), Grace(TM) GraceResolv(TM) Silica Flash Cartridge (4) ~120g) or on normal phase silica using pre-packed cartridges such as Agela Flash Colum Silica-CS cartridges (80~330g), or using manual or Grace Reveleris® X2 Flash systems or similar systems performed on reversed-phase silica using an automated Agela Technologies C-18, spherical cartridge (20–35 μm, 100A, 80–330 g); (vii) preparative reversed-phase HPLC and preparative reversed-phase SFC, respectively, using isocratic concentrations or gradients of mobile phase as described in the experimental section and one of the following methods as described below: It was performed using standard HPLC and SFC equipment with either MS and / or UV operated fraction collection equipment.

[0348] HPLC preparative method: Preparative method A: Compounds are collected in H 2 MeCN / NH in O 4 HCO 3 Purified by preparative HPLC on a YMC-Actus Triart C18 ExRS column (5 μm, 150 × 30 mm ID) using a gradient of (10 mM); preparative method B: compounds were purified using H2 MeCN / NH in O 4 HCO 3 (10mM) / NH 3 Purified by preparative HPLC on an XBridge™ C18 OBD column (5 μm, 150 x 30 mm ID) using a gradient of (0.1%, aq) buffer system; Preparative Method C: Compounds were As H 2 Purified by preparative HPLC on an XSelect CSH OBD column (5 μm, 150 × 30 mm ID) using a gradient of MeCN / FA (0.1%) in O; preparative method D: Compounds were H 2 Purified by preparative HPLC on an XSelect CSH C18 OBD column (5 μm, 250 × 19 mm ID) using a gradient of MeCN / FA (0.1%) in O; As H 2 Preparative method F: The compound was purified by preparative HPLC on a Kromasil C8 column (10 μm, 250 × 20 mm ID) using a gradient of MeCN / MeCN / FA (95 / 5 / 0.2) in O , H as mobile phase 2 Purified by preparative HPLC on a Waters™ Sunfire™ C18 OBD column (5 μm, 150 x 30 mm ID) using a gradient of MeCN / FA (0.1%) in O; Preparative Method G : Compounds are prepared using H as the mobile phase. 2 Preparative method H: The compound was purified by preparative HPLC on a Kromasil C8 column (10 μm, 250 × 50 mm ID) using a gradient of MeCN / MeCN / FA (95 / 5 / 0.2) in O , H as mobile phase 2 MeCN / MeCN / NH in O 3 Purified by preparative HPLC on an XBridge™ C18 column (10 μm, 250 x 50 mm ID) using a gradient of (95 / 5 / 0.2); 2 MeCN / NH in O 4 HCO 3 Purified by preparative HPLC on an XBridge™ C18 OBD column (5 μm, 250 x 19 mm ID) using a gradient of (10 mM); 2 MeCN / MeCN / NH in O 3 Purified by preparative HPLC on an XBridge™ C18 column (10 μm, 250 x 19 mm ID) using a gradient of (95 / 5 / 0.2); 2 MeCN / NH in O 4 HCO 3 Purified by preparative HPLC on an XBridge™ C18 column (5 μm, 250 x 19 mm ID) using a gradient of (10 mM); 2 Purified by preparative HPLC on an XBridge™ Shield C18 column (5 μm, 150 x 30 mm ID) using a gradient of MeCN / FA (0.1%) in O; Preparative Method Q: The compound was H as mobile phase 2 MeCN / NH in O 3 Purified by preparative HPLC on an XBridge™ C18 ODB column (5 μm, 150 x 19 mm ID) using a gradient of (0.2%, pH 10) buffer system; As H 2 MeCN / NH in O 4 HCO 3 Purified by preparative HPLC on an XBridge™ C18 OBD column (5 μm, 150 x 30 mm ID) using a gradient of (10 mM); 2 MeCN / NH in O 4 C.O. 3 (10mM) / NH 3 Purified by preparative HPLC on an XBridge™ Shield C18 column (5 μm, 150 x 30 mm ID) using a gradient of (0.1%, aq) buffer system; As H 2 Preparative method V: The compound was purified by preparative HPLC on an XSelect CSH F-phenyl OBD column (5 μm, 250 × 19 mm ID) using a gradient of MeCN / FA (0.1%) in O H as mobile phase 2 Purified by preparative HPLC on a Waters™ Sunfire™ C18 OBD column (5 μm, 150 x 30 mm ID) using a gradient of MeCN / FA (0.1 M) in O; Preparative Method : Compounds were purified by preparative HPLC on an XSelect CSH OBD column (5 μm, 150 × 30 mm ID) using a gradient of MeCN / FA (0.1%) in H2O as the mobile phase;

[0349] SFC preparative method: Preparative method SFC-A: Compounds are collected using CO as the mobile phase. 2 Purified by preparative SFC on a Phenomenex Luna® HILIC column (5 μm, 250 x 30 mm ID) using EtOH / FA (20 mM) in CO as a phase 2 MeOH / 2M NH in MeOH 3 (99.5 / 0.5) was purified by preparative SFC on DAICEL DCpak® P4VP (5 μm, 250 x 20 mm ID); preparative method SFC-C: compounds were purified with CO as the mobile phase 2 MeOH / H inside 2 O(NH 3 50mM) (97 / 3) on Waters™ BEH (5μm, 250 x 30mm ID); preparative method SFC-D: Compounds were purified using CO 2 Purified by preparative SFC on Waters™ BEH (5 μm, 30 x 250 mm ID) using EtOH / FA (20 mM) in 2 MeOH / NH in 3 (20mM) was purified by preparative SFC on Waters™ BEH (5μm, 250 x 30mm ID); preparative method SFC-G: compounds were purified with CO as the mobile phase. 2 MeOH / NH in 3 (20mM) was purified by preparative SFC on Waters™ BEH (3.5μm, 100 x 3mm ID); Preparative method SFC-H: Compounds were purified with CO as the mobile phase. 2 MeOH / NH in 3 (20 mM) was purified by preparative SFC on a Phenomenex Luna® HILIC column (5 μm, 250×30 mm ID).

[0350] Appropriate fractions were collected, combined and lyophilized to obtain the purified compound or appropriate fractions were collected, combined, concentrated under reduced pressure, extracted with DCM or EtOAc and the organic phase was Na 2 S.O. 4 Drying on top or by using a phase separator followed by concentration under reduced pressure afforded the purified compound; (viii) chiral preparative chromatography, either isocratic or gradient performed using HPLC or SFC on standard HPLC or SFC equipment, respectively, and with mobile phase as described in the experimental section; executed using; (x) Yields, if any, were not necessarily the maximum achievable; reactions were repeated if necessary and larger amounts of reaction product were required; (xi) If a particular compound is obtained as an acid addition salt, e.g. monohydrochloride or dihydrochloride, the stoichiometry of the salt will depend on the exact chemistry of the salt, based on the number and nature of basic groups in the compound. Stoichiometry was generally not determined by e.g. elemental analysis data; (xii) In general, the structure of the final product of formula (I) was confirmed by nuclear magnetic resonance (NMR) and / or mass spectrometry techniques; proton NMR chemical shift values ​​of 300, 400, 500 and 600 MHz, respectively. 1 Measurements were made on a delta scale using Bruker Avance III 300, 400, 500 and 600 spectrometers operating at the H frequency. Experiments were typically recorded at 25°C. Chemical shifts are given in ppm with solvent as internal standard. Protons on heteroatoms such as NH and OH protons are reported only when detected by NMR and may not be listed. In certain instances, protons may be masked or partially masked by the solvent peak, resulting in them being undescribed, unreported, or reported as multiple overlaps with the solvent. The following abbreviations are used (and their derivatives, e.g. dd, doublet for doublet, etc.): s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; qn, quintet; p, quintet; In some cases, the structure of the final product of formula (I) may appear as a rotamer in the NMR-spectrum, in which case only the main rotamer peak is reported. Electrospray mass spectral data are acquired using a Waters Acquity UPLC connected to a Waters single quadrupole mass spectrometer or similar instrument that acquires both positive and negative ion data, generally related to the parent structure. High-resolution electrospray mass spectral data are reported using a Waters Acquity XEVO qToF mass spectrometer or similar instrument coupled to a Waters Acquity UPLC to acquire positive and negative ion data. Only ions obtained and generally related to the parent structure are reported. (xiii) intermediates were not necessarily completely purified, but their structure and purity were assessed by TLC, analytical HPLC / UPLC, and / or NMR analysis and / or mass spectrometry; (xiv) Unless otherwise specified, compounds containing asymmetric carbon and / or sulfur atoms were not resolved; (xv) In general, examples and intermediate compounds are named using ChemDraw Professional version 19.0.0.22 from PerkinElmer. ChemDraw Professional version 19.0.0.22 generates names for chemical structures using the Cahn-Ingold-Prelog (CIP) ranking rules for stereochemistry and follows IUPAC rules as closely as possible when generating chemical names. Stereoisomers differ from each other in the stereographic symbols cited in the name and are assigned according to CIP rules.

[0351] ChemDraw optionally uses labels in the graphical depiction of stereocenters such as "&" and "or" to describe the configuration of stereochemical centers present in a structure. In general, chemical structures of examples and intermediates containing the label "&" at a stereocenter indicate that the configuration of such examples or intermediates at that stereocenter is a mixture of both (R) and (S). ; the label "or" means that the configuration of such example or intermediate at the stereocenter in question is either (S) or (R). Absolute stereocenters, unspecified stereocenters, "&" stereocenters, and "or" stereocenters can all exist in a single structure.

[0352] Generally, for examples and intermediate structures where all stereocenters are designated as "&", the structure is named with a "rac-" prefix. For examples and intermediate structures where all stereocenters are designated as "or", the structure is named with a "rel-" prefix.

[0353] Examples and intermediate compounds are generally referred to as "&" for chemical structures having multiple chiral centers, only some of which are designated as "&" using the designations (RS) and (SR). Named to display the center. The designations (R*) and (S*) are used to indicate the general "or" center for chemical structures having multiple chiral centers, only some of which are designated as "or."

[0354] Generally, the designations (r) and (s) are used to describe the absolute configuration of any pseudoasymmetric centers in the structures of examples and intermediates.

[0355] Generally, the label "isomer 1" corresponds to the first eluted isomer on a given chiral HPLC column, and "isomer 2" corresponds to the second eluted isomer on a given chiral HPLC column. Corresponds to isomers and is used to distinguish between two isomers that contain one or more stereocenters with unknown absolute configuration. (xvi) When referring to a reaction being degassed or purged, this is carried out, for example, by purging the reaction solvent with a constant flow rate of nitrogen for a suitable period of time (e.g. 5-10 minutes). can be done (xvii) In addition to the above, the following abbreviations are used:

[0356]

table 1

[0357] [Table 2]

[0358] [Table 3]

[0359] B. Intermediate compounds Intermediate 1: tert-butyl (R)-4-cyanothiazolidine-3-carboxylate [ka]

[0360] Step a) tert-butyl(R)-4-carbamoylthiazolidine-3-carboxylate [ka] Boc 2 O (18.6 mL, 80.2 mmol) was dissolved in (R)-3-(tert-butoxycarbonyl)thiazolidine-4-carboxylic acid (17.0 g, 72.9 mmol) and pyridine (7.07 mL, 87.5 mmol) in EtOAc (170 mL). and the reaction mixture was stirred at room temperature for 3 hours. Then, N.H. 3 A solution of (aq, 25%, 6 mL) was added dropwise and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc, the phases were separated, the organic phase was washed with saturated NaCl, dried, filtered through a pad of silica gel, washed with EtOAc and evaporated to give the crude title product as a colorless oil. The compound (16.9g, 100%) was obtained and used directly in the next step.

[0361] Step b) tert-butyl (R)-4-cyanothiazolidine-3-carboxylate TFAA (12.4 mL, 87.5 mmol) as a solution in EtOAc (20 mL) was prepared from crude tert-butyl (R)-4-carbamoylthiazolidine-3-carboxylate (16.9 g, 72.9 mmol) in EtOAc (150 mL). and pyridine (14.7 mL, 182 mmol) at room temperature. The mixture was stirred at room temperature for 4 h, then diluted with EtOAc, aq. HCl (1M), and saturated NaHCO 3 Washed with. The organic phase was dried, filtered through a pad of silica gel, washed with EtOAc and evaporated to give a pale yellow oil which solidified on standing. The crude solid material was suspended in heptane:EtOAc (4:1, 50 mL) and stirred at room temperature overnight. The solid was filtered off, washed with heptane:EtOAc (4:1), and dried to give the title compound (12.0 g, 83%) as a colorless solid; 1 H NMR(400MHz, CDCl 3 )δ 5.20-4.79(m,1H),4.60-4.53(m,1H),4.53-4.36(m,1H),3.40-3.18(m,2H),1.51(s,9H).

[0362] Intermediate 2: (R)-thiazolidine-4-carbonitrile hydrochloride [ka] A solution of aqHCl (12M, 11 mL) in MeOH (140 mL) was added to a solution of (R)-4-cyanothiazolidine-3-carboxylic acid tert-butyl intermediate 1 (6.0 g, 28 mmol) in MeOH (140 mL). Add slowly at room temperature. The clear colorless solution was stirred at room temperature for 2 hours. Evaporation of the solvent gave the title compound (4.22g, 100%) as a colorless solid; 1 H NMR(400MHz,CD 3 OD)δ 4.90(dd,1H),4.35-4.24(m,2H),3.37-3.24(m,2H).

[0363] Intermediate 3: tert-butyl (R)-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)carbamate [ka] DIPEA (19.6 mL, 112 mmol) was combined with (R)-thiazolidine-4-carbonitrile hydrochloride intermediate 2 (4.22 g, 28 mmol), (tert-butoxycarbonyl)glycine (6.13 g, 35.0 mmol) in EtOAc (120 mL). ) and T3P (41.6 mL, 70.0 mmol, 50% solution in EtOAc). The mixture was heated at 60°C for 4 hours. The mixture was diluted with EtOAc, water, aqHCl (1M) and saturated NaHCO 3 Washed sequentially with The organic phase was dried, filtered and evaporated. The residue was filtered through a pad of silica gel, washed with heptane:EtOAc (1:1) and evaporated to give an oil which was triturated with heptane:DCM to give the title product as an almost colorless solid. Compound (7.60g, 100%) was obtained; 1 H NMR(400MHz, CDCl 3 )δ 5.36-5.25(m,2H),4.59-4.52(m,2H),4.14-3.90(m,2H),3.29(d,2H),1.45(s,9H).

[0364] Intermediate 4: (R)-3-glycylthiazolidine-4-carbonitrile hydrochloride [ka] A solution of aqHCl (12M, 5.6mL) in MeOH (140mL) was prepared using tert-butyl (R)-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)carbamate in MeOH (140mL). It was added slowly to a solution of Intermediate 3 (7.60 g, 28.0 mmol) and the solution was then stirred at room temperature overnight. Evaporation of the solvent gave the title compound (5.80 g, 100%) as a colorless solid; 1 H NMR(400MHz,CD 3 OD)δ 5.34(t,1H),4.72(d,1H),4.62(d,1H),4.11-3.94(m,2H),3.41-3.36(m,2H).

[0365] Intermediate 5: Ethyl 6-(1,2-oxazinan-2-yl)quinoline-4-carboxylate [ka] 1,2-oxazinane hydrochloride (37 mg, 0.30 mmol) was dissolved in ethyl 6-br...

Claims

1. The following structure: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof.

2. The following structure: 【Chemistry 2】 The compound according to claim 1 or a salt thereof, which is a non-salt form compound of (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide having the formula:

3. The following structure: 【Chemistry 3】 The compound according to claim 1, which is a pharma- ceutically acceptable salt of (R)-N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide having the formula:

4. A pharmaceutical composition comprising the compound according to any one of claims 1 to 3 or a salt thereof, and one or more pharma- ceutically acceptable excipients.

5. A medicament for treating or preventing a liver disease, comprising the compound according to any one of claims 1 to 3 or a salt thereof.

6. The pharmaceutical composition according to claim 5, wherein the liver disease is non-alcoholic steatohepatitis.